US.JNJ · Johnson & Johnson

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 2,
      "details": {
        "atrPct": 1.8882838573686982,
        "turnoverUsdM": 2055.51458,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.JNJ",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 219.12,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2.5,
        "rsi_score": 0.5,
        "macd_score": 3,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 3.8,
      "take_profit_price": 239.106,
      "target_multiplier": 1.9,
      "technical_strength": 1.92,
      "take_profit_percent": 5
    },
    "positionPoints": 2,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.3239534883720931,
    "stopLossPercent": 3.7765677147373964,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 85.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 65.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 20
  },
  "market": {
    "ma20": 213.8295,
    "ma50": 208.8708,
    "close": 227.72,
    "prevClose": 224.44,
    "avgVolume20": 8935190,
    "volumeRatio": 1.01,
    "changePercent": 1.46
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred+database-backfill-market-proxy"
  },
  "barCount": 151,
  "momentum": {
    "max": 50,
    "result": 20,
    "details": {
      "ret_5d": 0.04453926767105165,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 20,
      "vcp_bonus": 0,
      "vol_ratio": 1.0373725335610384,
      "ret_points": 8,
      "vol_points": 2,
      "range_ratio": 0.6270941220214777,
      "volat_points": 0,
      "day_range_pct": 0.010934516072369529,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 8,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": true,
      "return_window_days": 5,
      "first_breakout_bonus": 2,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 85.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.4,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 88,
        "contribution": 4.4
      },
      {
        "raw": 16.4,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 82,
        "contribution": 16.4
      },
      {
        "raw": 11.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 74.67,
        "contribution": 11.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 78,
        "contribution": 7.8
      },
      {
        "raw": 20.3,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 67.67,
        "contribution": 20.3
      },
      {
        "raw": 3,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 30,
        "contribution": 3
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 65.1,
    "details": [
      "基本面分析總分: 4.4/5分",
      "資金流分析總分: 16.4/20分",
      "市場環境分析總分: 11.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.8/10分",
      "技術信號分析總分: 20.3/30分",
      "情緒分析: 3/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.4,
      "資金流": 16.4,
      "市場環境": 11.2,
      "情緒分析": 3,
      "技術信號": 20.3,
      "風險管理": 7.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.6,
          "turnoverUsdM": 2055.51458,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.4,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "優秀",
        "items": {
          "cmfPoints": 4,
          "mfiPoints": 4,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.JNJ",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred+database-backfill-market-proxy",
              "vixClose": 16.35
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 122.49652581928657,
                "ma50": 120.14779050838156,
                "name": "QQQ",
                "close": 124.95239259724464,
                "points": 2
              },
              "spy": {
                "ma20": 113.40892631952988,
                "ma50": 111.00911273812379,
                "name": "SPY",
                "close": 114.0946256142667,
                "points": 2
              },
              "source": "twelvedata+fred+database-backfill-market-proxy"
            }
          },
          "atrPct": 1.8882838573686982,
          "atrPoints": 4,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 3,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 1,
              "sentimentScoreRaw": 0.3
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 140685268,
                "url": "https://finnhub.io/api/news?id=d96abf3bf94a147bdb7a7b2142321323483cc1cf5ce22841a29c097bd4296175",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader market did that week. Earned income depends on showing up. Dividend income depends on a board of directors ... Own 500 Shares of Pfizer and JNJ and Here’s Your Annual Dividend Income",
                "category": "company",
                "datetime": 1782055806,
                "headline": "Own 500 Shares of Pfizer and JNJ and Here’s Your Annual Dividend Income"
              },
              {
                "id": 140675625,
                "url": "https://finnhub.io/api/news?id=e85a798399e1fec70b5df4ed0ed3c88febae511cc49da22212df0beab87132e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson’s model fair value sits at US$252.87 per share, with analysts keeping price targets anchored to that unchanged estimate. Recent research links those steady targets to a mix of optimism around Icotyde, Inlexzo and the broader drug pipeline, balanced against policy questions and partnership headwinds that could influence how investors think about execution risk. As you read on, you will see how these moving pieces shape the evolving Johnson & Johnson story and what to watch...",
                "category": "company",
                "datetime": 1781921200,
                "headline": "Johnson & Johnson (JNJ) Stock Draws Fresh Price Target Split On Pipeline Promise And Policy Risk"
              },
              {
                "id": 140672114,
                "url": "https://finnhub.io/api/news?id=0ba5716f59465e1a317bda7071357617881c446ff9219f2f0681b844dada0fed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
                "category": "company",
                "datetime": 1781883903,
                "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice"
              },
              {
                "id": 140666607,
                "url": "https://finnhub.io/api/news?id=fdb76ff079ef0a95f1ef7f3563e45f92e8927748c4dc061249ac306bdfe2b254",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) reached $228.39 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.",
                "category": "company",
                "datetime": 1781819103,
                "headline": "Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade"
              },
              {
                "id": 140657247,
                "url": "https://finnhub.io/api/news?id=a42c0b28ad9e3db9a5e7daf40dc2477f33831feb15ec92e04d9a5581027395f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported Phase 3 results for TALVEY plus DARZALEX FASPRO in relapsed or refractory multiple myeloma, showing improved outcomes versus standard regimens. The MonumenTAL-3 study is the first to show a GPRC5D bispecific antibody combination achieving these results in earlier treatment lines. Findings were published in The New England Journal of Medicine and presented at a major scientific meeting, highlighting clinical and commercial relevance. Johnson & Johnson...",
                "category": "company",
                "datetime": 1781727340,
                "headline": "Johnson & Johnson (JNJ) Reports Phase 3 Myeloma Win For TALVEY Combination"
              },
              {
                "id": 140653506,
                "url": "https://finnhub.io/api/news?id=729ef1464eed7925c7eae947caa1a665935b7e626b883dc8e93bcf554d58f213",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1781701207,
                "headline": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know"
              },
              {
                "id": 140641294,
                "url": "https://finnhub.io/api/news?id=44985ee443132ff40a9df581cfb6d6d38d766e613efbcc80ee3bef11e0b28c69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Wondering if Johnson & Johnson at around US$235.66 is still a solid deal or starting to look fully priced? This article walks through the numbers so you can judge the stock's value with more confidence. The stock closed at US$235.66 and has returns of 1.5% over 7 days, 3.9% over 30 days, 13.7% year to date, 55.6% over 1 year, 56.6% over 3 years, and 65.6% over 5 years. This gives useful context before looking at valuation. Recent headlines around Johnson & Johnson have focused on its...",
                "category": "company",
                "datetime": 1781562105,
                "headline": "Johnson & Johnson (JNJ) Stock After 55% One-Year Surge Is There Still Value Here"
              },
              {
                "id": 140633576,
                "url": "https://finnhub.io/api/news?id=1a070fdd4a48facabaa8402dae777ea90b8d9c1211cdc2d234a671a39b764361",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Leerink Partners discussed the firm on May 13th as […]",
                "category": "company",
                "datetime": 1781464089,
                "headline": "Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained"
              }
            ],
            "raw_source": [
              {
                "id": 140687069,
                "url": "https://finnhub.io/api/news?id=038182b20706846a8396b0e55102890345a59ae8195727fb4930bad0bb58f9f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about 3% year-to-date while the broader market grinds higher. The good news for XLV holders: the fund has clawed back roughly 14% over the past year, and the 2026 setup looks meaningfully different from the policy ... The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026",
                "category": "company",
                "datetime": 1782073047,
                "headline": "The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026"
              },
              {
                "id": 140685268,
                "url": "https://finnhub.io/api/news?id=d96abf3bf94a147bdb7a7b2142321323483cc1cf5ce22841a29c097bd4296175",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Passive income is the closest thing investors have to financial gravity. It pulls in money whether you are at your desk, on a beach, or asleep, and it lands in your account no matter what the broader market did that week. Earned income depends on showing up. Dividend income depends on a board of directors ... Own 500 Shares of Pfizer and JNJ and Here’s Your Annual Dividend Income",
                "category": "company",
                "datetime": 1782055806,
                "headline": "Own 500 Shares of Pfizer and JNJ and Here’s Your Annual Dividend Income"
              },
              {
                "id": 140685278,
                "url": "https://finnhub.io/api/news?id=1c41598fa67f305357ade6684b9b7663a9eaab70be5aa4b45e9100089f109355",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Our Johnson & Johnson (NYSE:JNJ) 24/7 Wall St. price target lands at $261.72, pointing to 11.28% upside from the current price of $235.18. Our recommendation is buy, and our model carries a 90% confidence level. JNJ has quietly become one of healthcare’s most reliable compounders again, with oncology firing and dividend support intact. Metric Value ... Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside",
                "category": "company",
                "datetime": 1782052211,
                "headline": "Pharma Momentum Fuels Johnson & Johnson’s Path to Double-Digit Upside"
              },
              {
                "id": 140683941,
                "url": "https://finnhub.io/api/news?id=d1560fede7c35a7b857d61d97ac65a13dae5b23f478e8b1139775d2033f8eb14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generating a six-figure income from a $500,000 portfolio through yield alone is largely unrealistic. Doing so would require a payout approaching 20%, a level that few investments can sustain for long. The more practical approach is to combine a reasonable starting yield with businesses that consistently increase their dividends. Over time, dividend growth and compounding ... The Dividend Growth Path That Turns $500,000 Into a Six-Figure Income Stream",
                "category": "company",
                "datetime": 1782035131,
                "headline": "The Dividend Growth Path That Turns $500,000 Into a Six-Figure Income Stream"
              },
              {
                "id": 140681029,
                "url": "https://finnhub.io/api/news?id=4c043014fb4454e345171874d247325a619688f10d561927e09e57b21b8e3713",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The average retired worker receives about $24,000 a year from Social Security. Add a modest part-time job, the kind many retirees take for supplemental income rather than career advancement, and total annual income often lands somewhere between $40,000 and $45,000 before taxes. For millions of retirees, that combination defines the retirement budget. A portfolio can ... This Dividend Portfolio Pays More Than Social Security and a Part-Time Job Combined",
                "category": "company",
                "datetime": 1781989050,
                "headline": "This Dividend Portfolio Pays More Than Social Security and a Part-Time Job Combined"
              },
              {
                "id": 140679498,
                "url": "https://finnhub.io/api/news?id=0127ecdf6d6968e0a7d1d08398bfac208342f25098236ab7f0e59a41ddf9615d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $2 million dividend portfolio may appear straightforward on paper, but the amount investors actually get to spend depends heavily on taxes. In California, the gap between gross portfolio income and after-tax cash flow can be substantial. Federal dividend tax rates, the net investment income tax, state income taxes, and the classification of each distribution ... What a $2 Million Dividend Portfolio Actually Pays After Taxes in California",
                "category": "company",
                "datetime": 1781976104,
                "headline": "What a $2 Million Dividend Portfolio Actually Pays After Taxes in California"
              },
              {
                "id": 140678112,
                "url": "https://finnhub.io/api/news?id=33713a80942c0f02782871d8bac1e827a75ef0a16d83d067322dbf43f072f609",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stryker Corporation (NYSE:SYK) was among the stocks on Jim Cramer’s radar on Mad Money, as he advised investors to care about where a stock is going, not where it has been. Toward the end of the lightning round, a caller asked if the stock is a buy, sell, or hold. In response, Cramer said: See, […]",
                "category": "company",
                "datetime": 1781962802,
                "headline": "Jim Cramer Says Stryker and Its Orthopedic Peers Are Facing a Real Tough Run"
              },
              {
                "id": 140675625,
                "url": "https://finnhub.io/api/news?id=e85a798399e1fec70b5df4ed0ed3c88febae511cc49da22212df0beab87132e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson’s model fair value sits at US$252.87 per share, with analysts keeping price targets anchored to that unchanged estimate. Recent research links those steady targets to a mix of optimism around Icotyde, Inlexzo and the broader drug pipeline, balanced against policy questions and partnership headwinds that could influence how investors think about execution risk. As you read on, you will see how these moving pieces shape the evolving Johnson & Johnson story and what to watch...",
                "category": "company",
                "datetime": 1781921200,
                "headline": "Johnson & Johnson (JNJ) Stock Draws Fresh Price Target Split On Pipeline Promise And Policy Risk"
              },
              {
                "id": 140673885,
                "url": "https://finnhub.io/api/news?id=a4ba10cc277dc5638d8a27ac98fd44bd7c13a6c0998fe9d98a77cb21ab77993b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $1 million portfolio is often discussed as though the balance itself answers the retirement question. It does not. What matters is the amount of income that ultimately reaches your bank account after taxes. The yield displayed on a brokerage statement is only the starting point. Federal taxes, state taxes, and the type of income ... The $1 Million Retirement Mistake: Counting Income You’ll Never Get to Spend",
                "category": "company",
                "datetime": 1781899414,
                "headline": "The $1 Million Retirement Mistake: Counting Income You’ll Never Get to Spend"
              },
              {
                "id": 140673043,
                "url": "https://finnhub.io/api/news?id=1486d542178c6437fd6835f7c083b5f7a14c8390fd7844c73aea933861d437f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Ten thousand dollars a month works out to $120,000 a year, an income stream that exceeds the roughly $68,359 in per-capita disposable personal income reported by the Bureau of Economic Analysis for the first quarter of 2026. For many retirees, that level of cash flow would support a lifestyle well above basic needs. The real ... The Retirement Portfolio That Forks Over a $10,000 Check Every Month",
                "category": "company",
                "datetime": 1781895387,
                "headline": "The Retirement Portfolio That Forks Over a $10,000 Check Every Month"
              },
              {
                "id": 140672113,
                "url": "https://finnhub.io/api/news?id=1fd9bc4642dde7dfca9556d7b686c96ca55f2d7e1a1c8835903fd2b5943187ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Bear markets are a part of investing life, but you can prepare for them ahead of time.",
                "category": "company",
                "datetime": 1781890500,
                "headline": "Smart Money Is Fleeing Tech for Johnson & Johnson Ahead of the Next Market Storm"
              },
              {
                "id": 140672114,
                "url": "https://finnhub.io/api/news?id=0ba5716f59465e1a317bda7071357617881c446ff9219f2f0681b844dada0fed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
                "category": "company",
                "datetime": 1781883903,
                "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice"
              },
              {
                "id": 140670651,
                "url": "https://finnhub.io/api/news?id=6ff9be3d43be9284c7893f726797cdb3adb20cc669295aa51690178cf4899212",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The stock market isn’t going to fall again, at least in this century. The S&P is up 8% this year. It is up 25% in the last year, and 80% over the last five. Some stocks of relatively well-known companies have doubled or better since January 1. Among the most extraordinary is the dying chip ... If You Think The Market Will Ever Fall, Buy This",
                "category": "company",
                "datetime": 1781877668,
                "headline": "If You Think The Market Will Ever Fall, Buy This"
              },
              {
                "id": 140669988,
                "url": "https://finnhub.io/api/news?id=d31eeabb917c968d5e82afb456e0ad85d5a7886dcafa679195603500fdb24d28",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.",
                "category": "company",
                "datetime": 1781870820,
                "headline": "J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?"
              },
              {
                "id": 140669838,
                "url": "https://finnhub.io/api/news?id=02a554c4616b88be08b547c300e8cfb1217b810ed5588adb0d448e868e75b690",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2268889196/image_2268889196.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "iShares BALI ETF review: 7.8% yield, conservative options overlay, lower volatility but capped upside and tax quirks.",
                "category": "company",
                "datetime": 1781861400,
                "headline": "BALI: A Hidden Covered Call ETF That Could Be Better Than You Think"
              },
              {
                "id": 140666607,
                "url": "https://finnhub.io/api/news?id=fdb76ff079ef0a95f1ef7f3563e45f92e8927748c4dc061249ac306bdfe2b254",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) reached $228.39 at the closing of the latest trading day, reflecting a -2.48% change compared to its last close.",
                "category": "company",
                "datetime": 1781819103,
                "headline": "Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade"
              },
              {
                "id": 140666073,
                "url": "https://finnhub.io/api/news?id=fb9687e70ef07cffd68567a72b392ddb98c9f48face7c4fa97082ff06f6f1050",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Dividend Kings include more than 50 stocks with steadily rising payouts. They’re hard to beat for dividend safety.",
                "category": "company",
                "datetime": 1781819100,
                "headline": "Stocks With 50 Years of Dividend Hikes"
              },
              {
                "id": 140666583,
                "url": "https://finnhub.io/api/news?id=d963d5dba60c21466c96ace725243b9ee26de74374436bbf32f8a7e7fb35b12f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Broadcom Inc. (AVGO) and Johnson & Johnson (JNJ), as well as two micro-cap stocks, Franklin Wireless Corp. (FKWL) and Park Aerospace Corp. (PKE).",
                "category": "company",
                "datetime": 1781816940,
                "headline": "Top Research Reports for Alphabet, Broadcom & Johnson & Johnson"
              },
              {
                "id": 140665981,
                "url": "https://finnhub.io/api/news?id=0b638c6ef191f5dbe4acd9d2334545c22003192c9ec27ab3ef212175c49ee56a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.",
                "category": "company",
                "datetime": 1781816249,
                "headline": "What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine?"
              },
              {
                "id": 140664854,
                "url": "https://finnhub.io/api/news?id=042c3b1b649362c19ab9ef08adc4605f661781d63c4e6cfb25d95d99a481aa76",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Get insights into the dow jones index performance on Thursday. Explore the top gainers and losers within the dow jones index in today's session.",
                "category": "company",
                "datetime": 1781809802,
                "headline": "Stay informed with the top movers within the dow jones index on Thursday."
              },
              {
                "id": 140663697,
                "url": "https://finnhub.io/api/news?id=cfd7591aeb47ea7d17a131f977bc09b5b9a674d16cce3c54f5b2ea1d24765b3d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1781800802,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 140663978,
                "url": "https://finnhub.io/api/news?id=603e63ae6fd2fffb0df402d01605ad1afced52f8767bb82e6f89217b05b81d14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Recently published Insomnia Market Insights report includes a comprehensive understanding of current treatment practices, insomnia emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
                "category": "company",
                "datetime": 1781800260,
                "headline": "Insomnia Market Witnesses Robust Growth During the Forecast Period (2026-2036) with Emerging Orexin Receptor Antagonists and Melatonin Receptor Agonist | DelveInsight"
              },
              {
                "id": 140663979,
                "url": "https://finnhub.io/api/news?id=2483c8197dab957a59a075bc5bd15a9d23c5c061fb3e1bcbc6c43845863a74f0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $2 million investment portfolio can generate a six-figure income stream without tenants, maintenance calls, property tax surprises, or vacancy risk. The arithmetic is straightforward. The challenge is deciding how much yield to pursue and understanding the trade-offs that come with it. To make a fair comparison, start with rental real estate. Many landlords aim ... This $2 Million Portfolio Pays a Six-Figure Income Without Owning a Single Rental Property",
                "category": "company",
                "datetime": 1781796893,
                "headline": "This $2 Million Portfolio Pays a Six-Figure Income Without Owning a Single Rental Property"
              },
              {
                "id": 140664959,
                "url": "https://finnhub.io/api/news?id=9374b6840ea88e42095b1ca64c948230a365197b4ca0ced35c3afe6da3f85ecd",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222145/image_2194222145.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Biohaven (BHVN) upgraded to Buy on FDA shifts and strong biomarker data.",
                "category": "company",
                "datetime": 1781796504,
                "headline": "Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations"
              },
              {
                "id": 140669985,
                "url": "https://finnhub.io/api/news?id=3befb971a581643ef5598128a12003139593bfcadd0c717c21c370431db4c2ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.",
                "category": "company",
                "datetime": 1781789400,
                "headline": "3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound"
              },
              {
                "id": 140660977,
                "url": "https://finnhub.io/api/news?id=512e984bdc248a350d1334b3c69a317b3a9e2f33ca21302ce299ef2bb5e5607e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Dividend Kings include more than 50 stocks with steadily rising payouts. They’re hard to beat for dividend safety.",
                "category": "company",
                "datetime": 1781759700,
                "headline": "50 Years of Dividend Hikes: These Stocks Did It"
              },
              {
                "id": 140659077,
                "url": "https://finnhub.io/api/news?id=c942a0d5c1591df0285590ed4a4acd0e8f1652aa88ba67bb4f3ba51f8a6ffc84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "With a net profit margin of 21.83%, Johnson & Johnson (NYSE:JNJ) is included among the 12 Most Profitable American Stocks to Buy in 2026. Johnson & Johnson (NYSE:JNJ) and its subsidiaries develop, manufacture, and sell a broad range of healthcare products, giving the company a presence across multiple areas of the healthcare industry. The company’s dividend […]",
                "category": "company",
                "datetime": 1781745378,
                "headline": "Johnson & Johnson to Invest Over $1 Billion in Florida Contact Lens Manufacturing Facility"
              },
              {
                "id": 140657247,
                "url": "https://finnhub.io/api/news?id=a42c0b28ad9e3db9a5e7daf40dc2477f33831feb15ec92e04d9a5581027395f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported Phase 3 results for TALVEY plus DARZALEX FASPRO in relapsed or refractory multiple myeloma, showing improved outcomes versus standard regimens. The MonumenTAL-3 study is the first to show a GPRC5D bispecific antibody combination achieving these results in earlier treatment lines. Findings were published in The New England Journal of Medicine and presented at a major scientific meeting, highlighting clinical and commercial relevance. Johnson & Johnson...",
                "category": "company",
                "datetime": 1781727340,
                "headline": "Johnson & Johnson (JNJ) Reports Phase 3 Myeloma Win For TALVEY Combination"
              },
              {
                "id": 140657196,
                "url": "https://finnhub.io/api/news?id=99db3e799002e4755db41c72785d08c5890ba5ae075dc663ed36d0ae55640a2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "US stocks (^DJI, ^IXIC, ^GSPC) ended Wednesday's session in negative territory after Federal Reserve officials unanimously voted to hold interest rates at their June FOMC meeting today, while also forecasting at least one possible rate hike ahead. Yahoo Finance Markets and Data Editor Jared Blikre breaks down the trading day's market reactions to the Fed's big decision. This was Kevin Warsh's first FOMC meeting he presided over as the new chairman of the Fed.",
                "category": "company",
                "datetime": 1781727325,
                "headline": "Nasdaq, US stocks slide as Fed forecasts possible rate hike"
              },
              {
                "id": 140671540,
                "url": "https://finnhub.io/api/news?id=b85f73c9839ef1c88922e1e344a59e1c8b958316f1c6760961e5524a9583e6e1",
                "image": "https://image.cnbcfm.com/api/v1/image/108323633-5ED3-MM-E-BLOCK-061726.jpg?v=1781738910&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "'Mad Money' host Jim Cramer weighs in on stocks including: Fair Isaac Corporation, Clover Health, Vistra, and Stryker Corporation.",
                "category": "company",
                "datetime": 1781726833,
                "headline": "Lightning Round: I like FICO but I am afraid it's going to be hurt by AI, says Jim Cramer"
              },
              {
                "id": 140657243,
                "url": "https://finnhub.io/api/news?id=634a02b07a423bd758fdabc74824f2bf8add6428668bfa1aa10e879383899ae4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.",
                "category": "company",
                "datetime": 1781725272,
                "headline": "J&J Has No Plans to Enter Obesity Drugs Market, CEO Says"
              },
              {
                "id": 140656173,
                "url": "https://finnhub.io/api/news?id=f0f2dd7436260c414875c9aa1536d6961ebc483832821a5160533334d45c0b3b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson is focusing on oncology and neuroscience instead of obesity drugs, with AI possibly supporting its next growth cycle.",
                "category": "company",
                "datetime": 1781724811,
                "headline": "J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030"
              },
              {
                "id": 140656099,
                "url": "https://finnhub.io/api/news?id=6aed0ff32822a8eb52845334c7ad811b5c613d870a175c4c627f1e454fb52a1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Kenvue offers both a great short-term and long-term payoff to investors.",
                "category": "company",
                "datetime": 1781723100,
                "headline": "1 Dividend King to Buy Hand Over Fist Right Now"
              },
              {
                "id": 140656174,
                "url": "https://finnhub.io/api/news?id=2aa3c28a6316d21cd0b3a250dbcd7a34faab4f462d8a0077eef69088034ae1a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.",
                "category": "company",
                "datetime": 1781720514,
                "headline": "Eli Lilly Stock's Trillion-Dollar Question"
              },
              {
                "id": 140654833,
                "url": "https://finnhub.io/api/news?id=0af54b09cc456b697d54b1cbe3268af507e3f7ce906b018927f8e52bf8c00d41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The company is promising a new era of accelerated growth, but the trajectory of one key cancer drug holds a subtle warning for investors.",
                "category": "company",
                "datetime": 1781716091,
                "headline": "The Number That Could Test Johnson & Johnson Stock"
              },
              {
                "id": 140654033,
                "url": "https://finnhub.io/api/news?id=e749f22e1737cb186dc50ac2df3f654e6717228c3f9942a26253a883c2118a28",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1781714402,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 140654836,
                "url": "https://finnhub.io/api/news?id=75650634439443a1b3278415e11c94f5fd9a43ed9188da817a87e5cdb95ed5fe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how much the company's multi-billion-dollar bet has fundamentally changed.",
                "category": "company",
                "datetime": 1781711865,
                "headline": "Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished"
              },
              {
                "id": 140653495,
                "url": "https://finnhub.io/api/news?id=64f524e7c802aae72c76b67af5053d767d174f5ba02db34221d989c067863105",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investing.com -- Johnson & Johnson will not enter the obesity drug market, Chief Executive Officer Joaquin Duato said Tuesday. The company plans to concentrate on cancer and neuroscience instead.",
                "category": "company",
                "datetime": 1781710609,
                "headline": "Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says"
              },
              {
                "id": 140653506,
                "url": "https://finnhub.io/api/news?id=729ef1464eed7925c7eae947caa1a665935b7e626b883dc8e93bcf554d58f213",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1781701207,
                "headline": "Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know"
              },
              {
                "id": 140653137,
                "url": "https://finnhub.io/api/news?id=d5350739b2d15278b849d4574e94072a6495e973c1e9932f9297e3b7998497d5",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.bloomberg.com/news/articles/2026-06-17/j-j-takes-a-pass-on-obesity-drugs-to-focus-efforts-on-cancer",
                "category": "company",
                "datetime": 1781692352,
                "headline": "'J&J Takes a Pass on Obesity Drugs to Focus Efforts on Cancer' - Bloomberg"
              },
              {
                "id": 140647896,
                "url": "https://finnhub.io/api/news?id=181ca142a7059e36d24eb48fc8529cee1579db14c91dc47072f2a24942687a4e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The average retired worker receives roughly $2,000 a month from Social Security. For many retirees, that covers only part of the budget. Building a second Social Security-sized check from dividends can help cover housing, healthcare, travel, family support, or simply provide a larger margin of safety in retirement. The challenge is not finding the right stock. ... How to Build $3,000 a Month in Dividend Income to Cover the Average Social Security Check",
                "category": "company",
                "datetime": 1781635748,
                "headline": "How to Build $3,000 a Month in Dividend Income to Cover the Average Social Security Check"
              },
              {
                "id": 140647897,
                "url": "https://finnhub.io/api/news?id=d237a874f4e0c3e3a5967426f5474fc5b327c4688766260351833c9b53a6c5a6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) spent 2025 proving it could lose a multibillion-dollar drug and still grow. Now it wants to show it can keep doing that for years. On June 13, the company reported results from a late-stage trial of its blood-cancer drug TALVEY, and the data landed at one of the year's ...",
                "category": "company",
                "datetime": 1781635620,
                "headline": "J&J drops key cancer trial results as Wall Street eyes stock"
              },
              {
                "id": 140647898,
                "url": "https://finnhub.io/api/news?id=e3bf0cad82f09b2c390edf1c9be4dc2c091cffbc1abb552e1300c5aba7556d7b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.",
                "category": "company",
                "datetime": 1781633880,
                "headline": "Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio?"
              },
              {
                "id": 140646832,
                "url": "https://finnhub.io/api/news?id=20ef33e725df0f990acc36eaa01d752303415a88b8b16b057523c8b90e3d2c06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The scenario looks like this: a 63-year-old has built up $850,000 over a working lifetime, watched 2022 and a few scary headlines since, and parked almost all of it in CDs, money market funds, and short Treasuries paying roughly 4%. That throws off about $34,000 a year in interest. It feels prudent. It is also ... Playing It Safe at 63 With $850,000 in Cash and Bonds Is Quietly Costing This Retiree About $34,000 a Year",
                "category": "company",
                "datetime": 1781630625,
                "headline": "Playing It Safe at 63 With $850,000 in Cash and Bonds Is Quietly Costing This Retiree About $34,000 a Year"
              },
              {
                "id": 140646833,
                "url": "https://finnhub.io/api/news?id=6bda336a7e2f6318c643e03235e642b774d4242d2f2455396703042ea2e9d0f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Joaquin Duato made the comments at a CEO summit in London, where he also said AI is already helping J&J develop medicines faster",
                "category": "company",
                "datetime": 1781628511,
                "headline": "J&J CEO says curing certain cancers within a decade is realistic"
              },
              {
                "id": 140646834,
                "url": "https://finnhub.io/api/news?id=df70a7015d868b897da7631774f8af95bba77553d8c1c207eef9411f5feb5031",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Monika Saxena joins the casual-dining chain after eight years as EVP of brand marketing at LongHorn Steakhouse.",
                "category": "company",
                "datetime": 1781628432,
                "headline": "BJ’s Restaurants hires Darden marketer as brand president"
              },
              {
                "id": 140645550,
                "url": "https://finnhub.io/api/news?id=322a611983811780d1211ebed8398e35452120dbde1210c1c2dd3473ad32c938",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.",
                "category": "company",
                "datetime": 1781618820,
                "headline": "AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?"
              },
              {
                "id": 140644888,
                "url": "https://finnhub.io/api/news?id=6eaabbb32fce2118aaf335297d381764ea1473629163110554ba198cd10e0b26",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.",
                "category": "company",
                "datetime": 1781615221,
                "headline": "Health Care ETFs: XLV Delivers Low Fees and Solid Returns"
              },
              {
                "id": 140645570,
                "url": "https://finnhub.io/api/news?id=6727ef7386ff3bd621e2ed7b6da0addc3e66ee142395c4e70a1daaec561b47db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The investment will add J&J’s manufacturing, packaging and distribution capabilities to meet growing demand for its contact lenses.",
                "category": "company",
                "datetime": 1781608620,
                "headline": "J&J commits $1B to expand contact lens production in Florida"
              },
              {
                "id": 140645571,
                "url": "https://finnhub.io/api/news?id=e5bf86e8bc53e829baeacee564a5f3a2c6b0ae9f37fd61e2cd4ef43499fca351",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Neumora’s stumble is the latest setback for a once-promising class of brain drugs. Elsewhere, a cell therapy manufacturing specialist took steps toward an IPO and J&J made its latest U.S investment.",
                "category": "company",
                "datetime": 1781600880,
                "headline": "Neumora depression drug fails; EnGene to cut 50% of staff"
              },
              {
                "id": 140641294,
                "url": "https://finnhub.io/api/news?id=44985ee443132ff40a9df581cfb6d6d38d766e613efbcc80ee3bef11e0b28c69",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Wondering if Johnson & Johnson at around US$235.66 is still a solid deal or starting to look fully priced? This article walks through the numbers so you can judge the stock's value with more confidence. The stock closed at US$235.66 and has returns of 1.5% over 7 days, 3.9% over 30 days, 13.7% year to date, 55.6% over 1 year, 56.6% over 3 years, and 65.6% over 5 years. This gives useful context before looking at valuation. Recent headlines around Johnson & Johnson have focused on its...",
                "category": "company",
                "datetime": 1781562105,
                "headline": "Johnson & Johnson (JNJ) Stock After 55% One-Year Surge Is There Still Value Here"
              },
              {
                "id": 140639467,
                "url": "https://finnhub.io/api/news?id=45d96341a355eed5c643fc24508153b0829c1da5af3f88702651d3714f07b3ec",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Monday.",
                "category": "company",
                "datetime": 1781550603,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 140639627,
                "url": "https://finnhub.io/api/news?id=812c951494e243a7131ed960df204ec414f40e3caa1cbca1394f9471b06b3ded",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Two retirees walk into retirement with the same amount of money. One builds a portfolio that pays $120,000 a year but barely grows. The other settles for $65,000 a year and focuses on dividend growth. At first glance, the first retiree appears to have won. Twenty-five years later, the second retiree may have collected more ... The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer",
                "category": "company",
                "datetime": 1781549965,
                "headline": "The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer"
              },
              {
                "id": 140638798,
                "url": "https://finnhub.io/api/news?id=3b5a5ccec14fdf2cc6423edabdac28bbcff8beb167504701c5780dbf58d3e0b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) was built for investors who want a paycheck that gets bigger every year, not a yield chase. DGRO tracks the Morningstar US Dividend Growth Index, screening for companies with at least five consecutive years of dividend growth and payout ratios under 75%. The fund pays a roughly 2.2% ... 64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends",
                "category": "company",
                "datetime": 1781542560,
                "headline": "64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends"
              },
              {
                "id": 140638876,
                "url": "https://finnhub.io/api/news?id=54bbaa689e337f67833f146d7e0110836da3a8434f3f616092394e8e9258ddf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The investment is anticipated to enhance J&J’s supply chain resilience regarding production of its ACUVUE contact lenses.",
                "category": "company",
                "datetime": 1781542215,
                "headline": "J&J outlays $1bn to strengthen Floridian contact lens manufacturing provision"
              },
              {
                "id": 140640058,
                "url": "https://finnhub.io/api/news?id=f61c4a89249754a85dfb7283e938392756afa6af2b7a749e3d674e81fa74d00d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2281005860/image_2281005860.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Sanofi looks compelling with strong fundamentals and a robust pipeline. Click for this updated look at SNY stock and why I remain strongly bullish.",
                "category": "company",
                "datetime": 1781542157,
                "headline": "Sanofi 'Strong Buy': Continued Dupxient Sales Growth And Sarclisa OBI First"
              },
              {
                "id": 140638877,
                "url": "https://finnhub.io/api/news?id=4b5fc3029d36b6128c6f82fb089c07b1711843d12a60f37b9e8580db825fd5b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A rank-and-file member of Congress earns $174,000 per year. A dividend portfolio can generate the same level of income without a campaign, constituents, or a weekly commute to Washington. Unlike a salary, however, this income is tied to capital, which means the size of the portfolio matters far more than the title attached to the ... This $1.7 Million Portfolio Pays More Than a Member of Congress",
                "category": "company",
                "datetime": 1781539112,
                "headline": "This $1.7 Million Portfolio Pays More Than a Member of Congress"
              },
              {
                "id": 140637911,
                "url": "https://finnhub.io/api/news?id=34c50db6c012e281a570b6af876f88fe84a025c86611854903a3f549ad77be5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "PFE trades at a steep discount as COVID sales fade and patent cliffs loom, but new products, oncology strength and pipeline plans could shape its future.",
                "category": "company",
                "datetime": 1781532240,
                "headline": "Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?"
              },
              {
                "id": 140637926,
                "url": "https://finnhub.io/api/news?id=f6c3ac4f2eac899c03de3640769fe63fd780477b1ec1be43958c5fa7184b6a8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AZN wins FDA approval to expand Truqap's use in PTEN-deficient prostate cancer, backed by phase III data showing improved outcomes and broader use.",
                "category": "company",
                "datetime": 1781528340,
                "headline": "AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication"
              },
              {
                "id": 140636695,
                "url": "https://finnhub.io/api/news?id=3f8bb3c0ad09ad65d056b8ae672cfa7b0443ff6d553aba4868813e96f0cf1063",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Although Wall Street has spent the better part of two years cheering an artificial intelligence buildout that has dragged the Nasdaq 100 up roughly 30% over the past year, the technology-packed Nasdaq Composite is starting to wobble at the worst possible moment. The benchmark S&P 500 has slipped, with SPY off about 4% in the ... Today’s AI market hits all 5 warning signs that preceded 2000 Nasdaq crash.",
                "category": "company",
                "datetime": 1781521440,
                "headline": "Today’s AI market hits all 5 warning signs that preceded 2000 Nasdaq crash."
              },
              {
                "id": 140636732,
                "url": "https://finnhub.io/api/news?id=2593d6ad56490d1d1f864046d6463f38ed8bff681afe6f61369d8ece5327710a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., June 15, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities.",
                "category": "company",
                "datetime": 1781517600,
                "headline": "Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida"
              },
              {
                "id": 140638878,
                "url": "https://finnhub.io/api/news?id=786a8f5fff5b797bb12b03e143d8154d1bc17c6b18524b2db589b13cf780e4cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.",
                "category": "company",
                "datetime": 1781516220,
                "headline": "J&J multiple myeloma drug gains edge in earlier stage disease"
              },
              {
                "id": 140638353,
                "url": "https://finnhub.io/api/news?id=407be7c56ab20c1341dab665020946792d07a14afd735c93cd5842a45df67e67",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company's U.S. Vision operations, enhance supply chain resilience, and meet the",
                "category": "company",
                "datetime": 1781503346,
                "headline": "Johnson & Johnson Plans $1B+ Florida Investment To Strengthen Its Vision Operations By Scaling Up Its Manufacturing, Packaging And Distribution Capabilities"
              },
              {
                "id": 140638354,
                "url": "https://finnhub.io/api/news?id=08f1ad40ebf89c92ee83c9a41d6d79cdccc9675bdbf63299dced90dfec206f78",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "TALVEY plus DARZALEX FASPRO with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the third positive study in recent months",
                "category": "company",
                "datetime": 1781493559,
                "headline": "Reported Saturday, Johnson & Johnson's TALVEY Plus DARZALEX FASPRO Delivers Up To 81% PFS And 89% OS At 24 Months In First Phase 3 Study To Show Superior PFS For GPRC5D Bispecific Combination In Multiple Myeloma"
              },
              {
                "id": 140634337,
                "url": "https://finnhub.io/api/news?id=ea6aca9d78024a271833cba5c009aad1ec358b2a9ddfd4a9876a25a12a3c3182",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported breakthrough Phase 2/3 ENERGY trial results for IMAAVY (nipocalimab) in warm autoimmune hemolytic anemia, a rare anemia with no current FDA approved therapies. The drug significantly improved hemoglobin levels and fatigue in trial patients, with a safety profile consistent with prior use. These data supported a supplemental Biologics License Application, which has received U.S. FDA Priority Review. IMAAVY is also being studied across multiple autoimmune...",
                "category": "company",
                "datetime": 1781479004,
                "headline": "IMAAVY Breakthrough And Priority Review Reframe Johnson And Johnson Growth Story"
              },
              {
                "id": 140633576,
                "url": "https://finnhub.io/api/news?id=1a070fdd4a48facabaa8402dae777ea90b8d9c1211cdc2d234a671a39b764361",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer. Johnson & Johnson (NYSE:JNJ)’s shares are up by 53% over the past year and by 15% year-to-date. Leerink Partners discussed the firm on May 13th as […]",
                "category": "company",
                "datetime": 1781464089,
                "headline": "Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained"
              },
              {
                "id": 140633577,
                "url": "https://finnhub.io/api/news?id=39fefa1de550a5eabf1e4db65dc06502e00b28e55891b27f0b68f0d4cab4776b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Building $3,000 a month in dividend income before age 50 can transform the way you think about work. While it may not fully replace a salary, it can cover a mortgage payment, health insurance, or a large share of household expenses, creating the freedom to reduce hours, change careers, take a sabbatical, or pursue work ... How to Build $3,000 a Month in Dividend Income Before You Turn 50",
                "category": "company",
                "datetime": 1781462771,
                "headline": "How to Build $3,000 a Month in Dividend Income Before You Turn 50"
              },
              {
                "id": 140632368,
                "url": "https://finnhub.io/api/news?id=6c3460a3ca10527b9f3f66ca00c059034987101dcf48ee410b78dafbed1cfcb2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $2 million dividend portfolio for retirement sounds like you’ve arrived. For a retired couple living in New York, however, the headline portfolio value tells only part of the story. What ultimately matters is not the income shown on a brokerage statement, but the amount that remains available to spend after taxes and other income-related ... What a $2 Million Dividend Portfolio Actually Pays a New York Retiree After Taxes",
                "category": "company",
                "datetime": 1781444083,
                "headline": "What a $2 Million Dividend Portfolio Actually Pays a New York Retiree After Taxes"
              },
              {
                "id": 140631924,
                "url": "https://finnhub.io/api/news?id=ee3ff0e3b56e156ea199a6f0582c2051edea44557aba56a8c4a32c391c3b83f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The average retired worker receives roughly $23,700 per year from Social Security. A $750,000 portfolio dedicated to income generation can surpass that figure at virtually any reasonable yield level. The question is not whether the portfolio can outproduce the average Social Security benefit. The question is how much risk must be taken to achieve that ... A $750,000 Portfolio That Quietly Pays You More Than the Average Social Security Check",
                "category": "company",
                "datetime": 1781432957,
                "headline": "A $750,000 Portfolio That Quietly Pays You More Than the Average Social Security Check"
              },
              {
                "id": 140631275,
                "url": "https://finnhub.io/api/news?id=db05685ed7fa9939ae3365a9c4f10eb47f5f7e051b4cac1ed50d0021974af520",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "BlackBerry's QNX software has secured new deployments in industrial automation, robotics, and medical AI. The QNX platform is being adopted in a new AI powered heart pump developed by Johnson & Johnson. These wins extend QNX beyond its traditional automotive base into additional embedded and safety critical use cases. For investors watching TSX:BB, this QNX expansion comes with the stock at CA$12.86 and strong recent momentum. The share price is up 51.3% over the past 30 days, 146.4% year...",
                "category": "company",
                "datetime": 1781421211,
                "headline": "BlackBerry QNX Extends Beyond Autos As Valuation Runs Ahead Of Targets"
              },
              {
                "id": 140627794,
                "url": "https://finnhub.io/api/news?id=ceb252907a933221f33d53aae3a8872321dc9acdd3052703a09d08ad7d321532",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A Super Bowl weekend is one of the most in-demand and expensive recurring trips in American life. Tickets, airfare, hotels, meals, and ground transportation commonly run $8,000 to $15,000 per couple, so a realistic annual budget lands near $12,000. Can your portfolio can pay for one every February without ever touching principal? That is the work ... A $650,000 Portfolio That Could Send You to the Super Bowl Every Year",
                "category": "company",
                "datetime": 1781360564,
                "headline": "A $650,000 Portfolio That Could Send You to the Super Bowl Every Year"
              },
              {
                "id": 140627241,
                "url": "https://finnhub.io/api/news?id=0b51978df099617cefd9651fea7344a6ea091638629442c982afb1b364d96360",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Paying $2,000 a month in rent is often described as throwing money away. Homeownership, by contrast, is treated as the only reliable path to wealth. Yet under the right conditions, a dividend portfolio large enough to cover your rent can leave you with greater flexibility and, in some cases, a larger net worth than owning ... Why a Dividend Portfolio That Pays Your Rent May Beat Homeownership by $500,000 Over 20 Years",
                "category": "company",
                "datetime": 1781352132,
                "headline": "Why a Dividend Portfolio That Pays Your Rent May Beat Homeownership by $500,000 Over 20 Years"
              },
              {
                "id": 140626800,
                "url": "https://finnhub.io/api/news?id=0d64aea2f1b0f7d469b88e2d8c58872d27b7b9565a3d49570f6008aef38a4231",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is one of the 7 Best Longevity Stocks to Buy Now. On June 8, 2026, Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Firefly Bio, Inc. for $1B in cash. Firefly Bio is advancing its proprietary Firelink degrader antibody conjugate platform, which is focused on KRAS-driven tumors. Johnson […]",
                "category": "company",
                "datetime": 1781347145,
                "headline": "Johnson & Johnson (JNJ) to Acquire Firefly Bio for $1B"
              },
              {
                "id": 140626801,
                "url": "https://finnhub.io/api/news?id=b763c68e2f4050b422cf4a5eca35335692913592e63bb5c725fa14157e33e530",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study showing that TALVEY® (talquetamab-tgvs), a GPRC5D bispecific antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72% and clinically meaningful reduction of up to 53% in the risk of death compared",
                "category": "company",
                "datetime": 1781346780,
                "headline": "New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma"
              },
              {
                "id": 140626974,
                "url": "https://finnhub.io/api/news?id=165eb34803915ddaf7bde63fe19056cb20f2c136cd955e9a49e9eaac53576e29",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1296010658/image_1296010658.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Protagonist Therapeutics (PTGX) outlook: FDA catalysts, milestone payments, high-margin royalties & strong cash runway through 2028.",
                "category": "company",
                "datetime": 1781340360,
                "headline": "Protagonist Therapeutics: A Royalty-Driven Biotech With Two Shots On Goal"
              },
              {
                "id": 140628107,
                "url": "https://finnhub.io/api/news?id=0940b6eabd2b1d63a59bd846fcdab872a0e564180d7d0ce847a929c3db6904c0",
                "image": "https://image.cnbcfm.com/api/v1/image/108320871-1781257909666-gettyimages-2278537978-AFP_B4LN4PW.jpeg?v=1781257999&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Switzerland votes on a population cap that could tighten immigration and put its EU free-movement agreement under pressure.",
                "category": "company",
                "datetime": 1781312401,
                "headline": "Switzerland is voting on whether to cap its population at 10 million. Here's what to know"
              },
              {
                "id": 140624151,
                "url": "https://finnhub.io/api/news?id=80176f238a27a6c532b24c1047da675193f45baa5949a5d564b7269b7c9fbea6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) closed at $240.87 in the latest trading session, marking a +1.07% move from the prior day.",
                "category": "company",
                "datetime": 1781300703,
                "headline": "Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts"
              },
              {
                "id": 140623024,
                "url": "https://finnhub.io/api/news?id=4c1cecfc6a5b34f3242c9306a4411f15028914ca85f4742fa17b7bb6e2552a12",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.",
                "category": "company",
                "datetime": 1781297590,
                "headline": "What Could Push JNJ Stock Higher From Here?"
              },
              {
                "id": 140621658,
                "url": "https://finnhub.io/api/news?id=2e2a3fc7e7a4d422193e4c2989be6faac1d902220b3f9aa978156c6b7de72b37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management raised the bar two months ago, but the stock just shrugged. Here’s why the market is waiting for proof, not promises.",
                "category": "company",
                "datetime": 1781291663,
                "headline": "JNJ Raised the Bar: So Why Is the Stock Standing Still?"
              },
              {
                "id": 140621316,
                "url": "https://finnhub.io/api/news?id=7799b4943b4070490c4c31469f624b75e45753e95bef0bca85f5be0499429bf9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1781291402,
                "headline": "Stay informed with the top movers within the dow jones index on Friday."
              },
              {
                "id": 140621611,
                "url": "https://finnhub.io/api/news?id=1d397d33f0b173297e5376f0187b943ae10cef3bd992546e2f7e0e45a4acb7cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Medical science's capabilities are catching up with what it knows about the genomics of disease. J&J just made sure it's better equipped to utilize the industry's newest capabilities.",
                "category": "company",
                "datetime": 1781288700,
                "headline": "Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of Cancer's Most \"Undruggable\" Targets. Why That's Very Good News for Investors."
              },
              {
                "id": 140621660,
                "url": "https://finnhub.io/api/news?id=f8b5833ae5cd5c0710eeadfbc082ec40dd987f82e4d361ab7dca811157ff0548",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eli Lilly's obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on price-sensitive consumers.",
                "category": "company",
                "datetime": 1781285513,
                "headline": "The Catch Hiding In Eli Lilly Stock's Growth Story"
              },
              {
                "id": 140622418,
                "url": "https://finnhub.io/api/news?id=dd102701c816572d3e01ccfbaf6ededd83ef5008639ee29fa3637547d98d3ab8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2239919557/image_2239919557.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Nanobiotix offers upside via broad radiotherapy platform adoption but faces clinical, operational, and dilution risks. Read more on NBTX stock here.",
                "category": "company",
                "datetime": 1781283517,
                "headline": "Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech"
              },
              {
                "id": 140618742,
                "url": "https://finnhub.io/api/news?id=875054174e28101df0a37abfd481e754d23547568cc44838e8775bab70788446",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Twelve thousand dollars a month in dividend income sounds simple enough until you start doing the math. Many investors assume they can reach that number with a seven-figure portfolio and a handful of high-yield stocks. In reality, the capital required ranges from about $1.4 million to more than $4 million, depending on the yield you ... How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)",
                "category": "company",
                "datetime": 1781278101,
                "headline": "How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)"
              },
              {
                "id": 140618743,
                "url": "https://finnhub.io/api/news?id=c879924dd803a7d42134a6c62ba63a1fcde2d3cc4dfc455193d9fb61a7fa3bb8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer commented on, saying that tech stocks cannot be trusted to lead anymore. Cramer mentioned the company while highlighting his current sentiment around drug stocks, as he remarked: Obviously, the other leadership groups are a little more palatable to me… Healthcare, eureka, I found it. This […]",
                "category": "company",
                "datetime": 1781275508,
                "headline": "Jim Cramer Says He Likes Drug Stocks Here As He Discusses Johnson & Johnson"
              },
              {
                "id": 140618744,
                "url": "https://finnhub.io/api/news?id=f223d854815a46406ebb5f0b8a021e29b7ea6c31d0d53b3b4e979dafdca44510",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Guinness Global Innovators, an investment management company, recently released its Q1 2026 quarterly investor update for its “Guinness Global Equity Income Fund”. A copy of the letter is available to download here. The Fund focuses on providing investors with global exposure to dividend-paying companies. In Q1 2026, the fund returned was -0.5% (GBP), compared to -1.6% […]",
                "category": "company",
                "datetime": 1781274490,
                "headline": "Johnson & Johnson (JNJ) Jumped on Market Optimism"
              },
              {
                "id": 140617351,
                "url": "https://finnhub.io/api/news?id=d6e34c1d2d49d1cbde03f1aac9816d33c92d64ffd9d6c0eeb535b61220f9b49d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $50,000 dividend income stream looks unimpressive next to a $100,000 high-yield payout. Twenty years later, the comparison may look very different. That is the entire case for dividend growth investing. The goal is not to maximize income in year one. It is to build an income stream that can keep growing long after a ... The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar",
                "category": "company",
                "datetime": 1781266705,
                "headline": "The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar"
              },
              {
                "id": 140616536,
                "url": "https://finnhub.io/api/news?id=5ec0dba7b2e538562a198030ab89184d33dc6c2a0ead6cc06a01802d44b4a988",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "If you own JPMorgan Equity Premium Income ETF (NYSEARCA:JEPI), you bought it for a reason that still holds. JEPI pays monthly. It leans on a defensive equity sleeve and runs a covered call overlay that turns volatility into income. It is the largest active ETF in the country, yielding near 8.2%. But a younger competitor now runs the same ... Forget JEPI, Goldman’s S&P Income ETF Has Beaten It by 42 Points Since Launch",
                "category": "company",
                "datetime": 1781263405,
                "headline": "Forget JEPI, Goldman’s S&P Income ETF Has Beaten It by 42 Points Since Launch"
              },
              {
                "id": 140616546,
                "url": "https://finnhub.io/api/news?id=9aec43a641625d72ca7e24bc0fa335aef6022ac8a68cc22492ee500914c8eff5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "New cancer therapies may help fund dividend growth.",
                "category": "company",
                "datetime": 1781260500,
                "headline": "AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend."
              },
              {
                "id": 140613028,
                "url": "https://finnhub.io/api/news?id=77567cf9d167c938819050bf50d0f4d088259d07c0b879c4f0337e3a97a146f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Is JNJ a good stock to buy? We came across a bullish thesis on Johnson & Johnson on Dividend School’s Substack by School of Investing. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson’s share was trading at $237.00 as of June 9th. JNJ’s trailing and forward P/E were 26.97 and 20.12 […]",
                "category": "company",
                "datetime": 1781209827,
                "headline": "Is Johnson & Johnson (JNJ) A Good Stock To Buy Now?"
              },
              {
                "id": 140613029,
                "url": "https://finnhub.io/api/news?id=d757f3784e220bd44259c8e28cf39b3c125613ec4a96853fcb1b9ae7626fad7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Event overview and recent stock performance Johnson & Johnson (JNJ) has drawn fresh attention after recent share price moves, with the stock up about 7.7% over the past month and roughly 15% year to date. See our latest analysis for Johnson & Johnson. The recent 7.7% 30 day share price return, alongside a 15.0% year to date share price return and a 1 year total shareholder return of 57.4%, points to momentum building as investors reassess Johnson & Johnson’s long term prospects and risk...",
                "category": "company",
                "datetime": 1781208751,
                "headline": "Assessing Johnson & Johnson (JNJ) Valuation After Recent Share Price Momentum"
              },
              {
                "id": 140610484,
                "url": "https://finnhub.io/api/news?id=98162ac477e8ca6a8610f6477879cd793a9a291f27dffd6f3d8d824309506014",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Before the stock surged, management was laying out a multi-billion-dollar growth story that directly contradicted consensus estimates, if you knew where to look.",
                "category": "company",
                "datetime": 1781200983,
                "headline": "Why Did Wall Street Misprice JNJ Stock?"
              },
              {
                "id": 140610485,
                "url": "https://finnhub.io/api/news?id=ad0c9b3a185becaae5a7f5df966488d4b469bbe3903296b8877a6aee1a2f6c3e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.",
                "category": "company",
                "datetime": 1781198640,
                "headline": "Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines"
              },
              {
                "id": 140608966,
                "url": "https://finnhub.io/api/news?id=a7810718200604cbc7cec05d366836518f9a65d2c790e80905f96397c0ca337c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A Utah couple with two children and four grandchildren nearby has a retirement goal that has nothing to do with yachts or sports cars. They want to be the grandparents who can say “yes.” Yes to helping with travel hockey. Yes to a week at the lake. Yes to Disney. Yes to contributing toward a ... The Retirement Portfolio for Grandparents Who Want to Say Yes",
                "category": "company",
                "datetime": 1781198545,
                "headline": "The Retirement Portfolio for Grandparents Who Want to Say Yes"
              },
              {
                "id": 140608967,
                "url": "https://finnhub.io/api/news?id=2ecff03d0b450632e89eebd9be7c2012d973a0860e03e946a9fd05a418569d7e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "I keep buying Johnson & Johnson (NYSE:JNJ) because the market keeps handing me a discount on a company that refuses to act like the slow, sleepy legacy name Wall Street wants to price it as. The Fed will say what it says this month. The headlines will do what headlines do. I am still hitting ... The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I’m Loading Up on Anyway",
                "category": "company",
                "datetime": 1781197680,
                "headline": "The Fed Is Poised to Shake Wall Street This Month: Here Is the 1 Dirt-Cheap Stock I’m Loading Up on Anyway"
              },
              {
                "id": 140620221,
                "url": "https://finnhub.io/api/news?id=3d97315c5db7c12822b7cff6a64ee11bc3e53a40354baff3e1eec621aea4a430",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "At $238.49, Johnson & Johnson (NYSE:JNJ) screens as fully valued, with conditions potentially improving on any macro-driven pullback to $228. JNJ just stacked a $1 billion cash acquisition of Firefly Bio on top of a raised 2026 outlook, right as a more dovish Fed leadership backdrop pushes capital toward defensive cash flows. JNJ is the ... Buy, Hold, or Sell: Johnson & Johnson Just Triggered a $1 Billion Oncology Bet. Is It a Buy at $238?",
                "category": "company",
                "datetime": 1781194055,
                "headline": "Buy, Hold, or Sell: Johnson & Johnson Just Triggered a $1 Billion Oncology Bet. Is It a Buy at $238?"
              },
              {
                "id": 140608946,
                "url": "https://finnhub.io/api/news?id=03b9e651c2baf03c20d0dcaa13bfddd00bf7b1ba1c87bd7df28fd61d6cc51b7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.",
                "category": "company",
                "datetime": 1781191560,
                "headline": "Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?"
              },
              {
                "id": 140607158,
                "url": "https://finnhub.io/api/news?id=3c086171ad440924801c08c55ea30adc68de6cbaf969ddcf317d8df1ae2fbe80",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Rare Autoimmune Disease Could Become New Growth Opportunity",
                "category": "company",
                "datetime": 1781189896,
                "headline": "Johnson & Johnson Eyes Rare Disease Expansion"
              },
              {
                "id": 140607159,
                "url": "https://finnhub.io/api/news?id=1cfe195eae4bcfe79c8d842e23956fe68a418324941904a71bfbd134b409a9da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "With the rate environment stabilizing in mid-2026, income investors are circling back to a familiar playbook: own the businesses that have raised payouts through every cycle in living memory. Dividend Kings and Aristocrats with 25-plus years of consecutive hikes offer a growing cash payment backed by durable franchises that the bond market still struggles to ... 3 No-Brainer Dividend Growth Stocks to Buy in June",
                "category": "company",
                "datetime": 1781189210,
                "headline": "3 No-Brainer Dividend Growth Stocks to Buy in June"
              },
              {
                "id": 140608567,
                "url": "https://finnhub.io/api/news?id=878e0117f831ccfc1d79fbb779dcccb4a95dec5b90e22707a0e1f11a40b9b62c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/11/Johnson--Johnson.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority Review.",
                "category": "company",
                "datetime": 1781181638,
                "headline": "Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder"
              },
              {
                "id": 140605990,
                "url": "https://finnhub.io/api/news?id=ecb33188fabd7258071c4a79c25aa48b65db98b85cad7c317932d54c5195418a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) has announced positive findings from its Phase 2/3 ENERGY clinical trial, with IMAAVY (nipocalimab-aahu) demonstrating statistically significant improvements in hemoglobin levels among patients with warm autoimmune hemolytic anemia compared with placebo. The results provide further support for the therapy as the company seeks regulatory approval for a condition that currently has no FDA-approved treatment options.",
                "category": "company",
                "datetime": 1781181616,
                "headline": "Johnson & Johnson Reports Strong Late-Stage Results for Rare Blood Disorder Therapy (JNJ)"
              },
              {
                "id": 140605991,
                "url": "https://finnhub.io/api/news?id=2c9e668852d7a2df108f6476b107e37ab962d46041bd07b7d6a8c475bdf1fa24",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "As medtech companies eye entry into the IVL space, Shockwave Medical is consolidating its position through innovation and ongoing data generation.",
                "category": "company",
                "datetime": 1781179574,
                "headline": "How Shockwave Medical plans to keep rivals at bay in burgeoning IVL sector"
              },
              {
                "id": 140605300,
                "url": "https://finnhub.io/api/news?id=bba00825c1721aefe5be8dcbfadba4fb16f6d0ed6fe8b05c2d38849666310f9a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JACKSONVILLE, Fla., June 11, 2026--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is an extended depth of focus (EDOF) lens designed to support visual clarity and quality for patients undergoing cataract surgery.3",
                "category": "company",
                "datetime": 1781178300,
                "headline": "Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients"
              },
              {
                "id": 140605301,
                "url": "https://finnhub.io/api/news?id=e9f2de20a4a0088eb2d183de9aa686278ce1e1043eb1a2b084a23a4b3beaa81a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A retired couple with a $2 million dividend-focused portfolio yielding roughly 6%, or $120,000 per year, watched their income stream fall by $14,400 during a difficult market period as covered-call funds, mortgage REITs, and business development companies trimmed distributions. Their annual income dropped to $105,600. They did not sell a share. Understanding why they were ... A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell",
                "category": "company",
                "datetime": 1781171856,
                "headline": "A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell"
              },
              {
                "id": 140604654,
                "url": "https://finnhub.io/api/news?id=b07f01129d8982fa1643f08c61b8e31fb5cf10d097c783a41ddaea1f4582b62a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intravascular lithotripsy (IVL) has experienced strong uptake since Shockwave Medical became the first to market in the space.",
                "category": "company",
                "datetime": 1781170967,
                "headline": "Podcast: How Shockwave Medical plans to keep rivals at bay in burgeoning IVL sector"
              },
              {
                "id": 140608568,
                "url": "https://finnhub.io/api/news?id=b33a9775be674538e3f119e9b975efec8711e565e33585b416342de0555e23ef",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Expanded U.S. availability paired with new patient lifestyle quiz encourages informed decision-making ahead of cataract surgery.Cataracts are one of the leading causes of vision impairment. Nearly 20% of Americans aged",
                "category": "company",
                "datetime": 1781164020,
                "headline": "Johnson & Johnson Expands US Roll-Out Of Latest Advancement In Presbyopia-Correcting Intraocular Lenses"
              },
              {
                "id": 140605302,
                "url": "https://finnhub.io/api/news?id=dc804ab663eb215eb0bdc8bab7529f255081640625d7e87367c95311bcac050b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Poolbeg Pharma PLC (AIM:POLB, OTC:POLBF, FRA:POLBF) said it has activated the first clinical site for its first-in-patient POLB 001 TOPICAL trial, moving its lead cancer immunotherapy programme into patient recruitment as interim data remains on track for summer 2026. The AIM-listed company...",
                "category": "company",
                "datetime": 1781160480,
                "headline": "Poolbeg Pharma shows clinical progress with latest updates"
              },
              {
                "id": 140604092,
                "url": "https://finnhub.io/api/news?id=a08fb70d1929809632bab32fa5c3d929df8bcb027d37359fedad783a618ea819",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable hemoglobin (Hgb) responseb with rapid onset of effect in patients with warm autoimmune hemolytic anemia (wAIHA)e in the 30 mg/kg treatment group,a compared with those who received placebo. The randomized, placebo-controlled trial demonstrated approximately three times as many patients achieved durabl",
                "category": "company",
                "datetime": 1781157780,
                "headline": "IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies"
              },
              {
                "id": 140608569,
                "url": "https://finnhub.io/api/news?id=de6fc2053da1f05d2daa2e6bd8fa8ace5d2366fa51bfc54a1e72a77e6ccc770f",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as early as Week 1c More patients treated with",
                "category": "company",
                "datetime": 1781147142,
                "headline": "Johnson & Johnson Says IMAAVY Showed Rapid And Durable Anemia Improvement In wAIHA, A Disease With No FDA-Approved Therapies"
              },
              {
                "id": 140600873,
                "url": "https://finnhub.io/api/news?id=c8c4541d34916d8d2692f2c58cb8633762a4bc106e8f4a3fe89f9b89131fbfc5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) is one of the biggest names in health care, and lately, its stock has been living up to the hype. Shares have climbed back toward record territory, while much of the market has been affected by a sharp sell-off in technology stocks. Now, the company is pumping fresh cash ...",
                "category": "company",
                "datetime": 1781132400,
                "headline": "Johnson & Johnson bets $1 billion on hard-to-treat cancer"
              },
              {
                "id": 140597421,
                "url": "https://finnhub.io/api/news?id=95b102c1f16da3d73746525ac09cf0ea912106f12086de6374486a0ab0f68013",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks fell late Wednesday afternoon with the NYSE Healthcare Index declining 0.8% and th",
                "category": "company",
                "datetime": 1781120006,
                "headline": "Sector Update: Healthcare Stocks Decline Late Afternoon"
              },
              {
                "id": 140597422,
                "url": "https://finnhub.io/api/news?id=196404097496a9392079e2dd25d84cfd9b6ac16569194c1bcad0c96d91dbd776",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A Los Angeles jury found Johnson & Johnson (NYSE:JNJ) and its subsidiaries liable in a talc trial linked to mesothelioma. The jury awarded US$32 million to the family of a woman whose fatal illness was tied to long term use of the company’s talc based baby powder. The verdict adds to ongoing legal and reputational pressure surrounding historical talc products and alleged asbestos contamination. Johnson & Johnson, a diversified healthcare company with pharmaceuticals, medical devices, and...",
                "category": "company",
                "datetime": 1781118926,
                "headline": "Talc Verdict Tests Johnson & Johnson Balance Of Legal Risk And Growth"
              },
              {
                "id": 140596961,
                "url": "https://finnhub.io/api/news?id=053fea32457bdc9084abf1e7ae1bf00fdcae9db1ccd65bd722c43edaaedad38c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movements of the dow jones index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1781118602,
                "headline": "Which dow jones stocks are moving on Wednesday?"
              },
              {
                "id": 140594719,
                "url": "https://finnhub.io/api/news?id=a776024e8740f6f39dbbd438ea4830713818e6353e142930f12318f6d5c2d9f5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1781109603,
                "headline": "Stay informed with the top movers within the dow jones index on Wednesday."
              },
              {
                "id": 140595714,
                "url": "https://finnhub.io/api/news?id=707d8f8b5fd5b1bdb198106178d9952801b0c01783b93e6402ce4ccfcf63e40d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "I keep buying NVIDIA, Eli Lilly, and Johnson & Johnson, and if a fire took my brokerage statement to zero tomorrow, those are the three tickers I would start typing in again on day one. They each do something I cannot replicate by being clever. Why the buy button stays active on NVIDIA NVIDIA (NASDAQ:NVDA) ... I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow",
                "category": "company",
                "datetime": 1781109551,
                "headline": "I Would Rebuild My Portfolio With Just These 3 Stocks If I Lost Everything Tomorrow"
              },
              {
                "id": 140593868,
                "url": "https://finnhub.io/api/news?id=396317368b021c2bd4d30b137f8f17531d3e5b4dbb07f525ce05c5665a7b7f67",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Ten thousand dollars a month in dividend income works out to $120,000 per year. That is enough to cover the rent on a luxury waterfront condo in Miami Beach, one of the most expensive rental markets in the country. The math that gets you there is simple: $120,000 divided by your portfolio yield equals the ... The Portfolio That Gets You a Waterfront Condo in Miami Beach",
                "category": "company",
                "datetime": 1781105097,
                "headline": "The Portfolio That Gets You a Waterfront Condo in Miami Beach"
              },
              {
                "id": 140593869,
                "url": "https://finnhub.io/api/news?id=5f0d62ff0e64787bed18691428efec3ad6aed895ef99f95847712b3b99280812",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "LOS ANGELES, June 10, 2026--A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma after years of exposure to an asbestos-contaminated talc product, finding Johnson & Johnson (NYSE: JNJ) and its subsidiaries liable for her illness.",
                "category": "company",
                "datetime": 1781104920,
                "headline": "Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial"
              },
              {
                "id": 140593774,
                "url": "https://finnhub.io/api/news?id=b7910e91b8fd5524b6cb5074740954f7736c75950ae9aee78e758000ccb5bb1e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is a rare long-duration compounder because it is the rare equity whose credit quality, dividend record, and demand profile collectively rival a sovereign bond while still compounding capital. Healthcare is the one expense Americans cannot defer, and Johnson & Johnson sits at the center of how that spending gets delivered. Pillar ... Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond",
                "category": "company",
                "datetime": 1781104858,
                "headline": "Got $1,000? 1 Healthcare King to Buy and Never Sell That Is Safer Than a Treasury Bond"
              },
              {
                "id": 140592791,
                "url": "https://finnhub.io/api/news?id=9579e84ea2f1c422c2045a8546ff6087780a7cc0199a356e2ad045a20711a4bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "FesariusTherapeutics, a commercial-stage medical technology company reimagining dermal repair, today announced the close of an oversubscribed $20 million Series A financing round. The round was anchored by Jefferson Life Sciences (JLS) and joined by Johnson & Johnson (through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc.), Empire State Development's NY Ventures, and the American Society of Plastic Surgeons (ASPS), marking its inaugural institutional invest",
                "category": "company",
                "datetime": 1781092800,
                "headline": "FesariusTherapeutics Closes Oversubscribed $20M Series A, Led by Jefferson Life Sciences, and Backed by NY Ventures, and the American Society of Plastic Surgeons"
              },
              {
                "id": 140592004,
                "url": "https://finnhub.io/api/news?id=866491f082bb60507c322c5821e7eb691286ca650f310f9880effd9d68ce80b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) was among the stocks Jim Cramer discussed on Mad Money, along with the recent sell-off in the market. Cramer was bullish on the stock during the episode, as he said: Now, you can make good money for a while if you go all in on what’s hot, but I never do […]",
                "category": "company",
                "datetime": 1781091392,
                "headline": "Jim Cramer Applauds Johnson & Johnson’s “Great New Drug Profits, Triple-A Balance Sheet”"
              },
              {
                "id": 140597201,
                "url": "https://finnhub.io/api/news?id=d76821b3c6d17394ea9eeef724fdf4e8f30a5635a6db9d82a9ac1629364be4a7",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "A Los Angeles jury has awarded $32 million to the family of a California woman who died from pleural mesothelioma after years of exposure to an asbestos-contaminated talc product, finding Johnson & Johnson (NYSE:JNJ)",
                "category": "company",
                "datetime": 1781090752,
                "headline": "Johnson & Johnson Fined $32M From Los Angeles Jury Over 2024 Death Of California Woman From Pleural Mesothelioma Due To Exposure To Asbestos-Contaminated Talc Product"
              },
              {
                "id": 140592005,
                "url": "https://finnhub.io/api/news?id=3df41f6bc338bcac55e13f29f8df1b6363f4c0070a64d9bdc06fc0039f07a123",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $35,000 annual income is roughly comparable to the Social Security benefits many retired couples receive each year. It is also about what a $1 million portfolio can generate when invested in dividend growth names like Johnson & Johnson (NYSE:JNJ), Coca-Cola (NYSE:KO), Procter & Gamble (NYSE:PG), and broad dividend ETFs. The interesting question is not ... The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep",
                "category": "company",
                "datetime": 1781089455,
                "headline": "The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep"
              },
              {
                "id": 140591400,
                "url": "https://finnhub.io/api/news?id=9abce8ccc53da5592950c32cec54f09f5868f91248de56c78857a82b0c07c3e1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ChatGPT breaks down how retirees generate $2,000 monthly passive income in 2026 from dividends, bonds, REITs, rentals and annuities with capital needed.",
                "category": "company",
                "datetime": 1781082605,
                "headline": "I Asked ChatGPT How Retirees Can Generate $2K Monthly in Passive Income in 2026: Here’s What It Recommended"
              },
              {
                "id": 140595033,
                "url": "https://finnhub.io/api/news?id=455383ff50849211e00fbfb8333c1a96f099c05be2f2158077cedc1290faaabe",
                "image": "https://image.cnbcfm.com/api/v1/image/108247161-1767203326279-gettyimages-2253536106-US_STOCKS.jpeg?v=1781049448&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "The S&P 500 and Nasdaq Composite fell in Tuesday's trading as chip stocks went back to their losing ways.",
                "category": "company",
                "datetime": 1781035080,
                "headline": "Wednesday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 140594847,
                "url": "https://finnhub.io/api/news?id=73ea8c2babf99c6844509692620d11c64de1a1774a580e1e2ea452ad99f28caa",
                "image": "https://image.cnbcfm.com/api/v1/image/108319232-3ED3-MM-A-BLOCK-060926.jpg?v=1781045911&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "'Mad Money' host Jim Cramer talks the state of the tech trade in the current market.",
                "category": "company",
                "datetime": 1781033213,
                "headline": "The only cure for too much supply is lower stock prices, says Jim Cramer"
              },
              {
                "id": 140584418,
                "url": "https://finnhub.io/api/news?id=acf87668e27ad9bef18fef1b66745f499e9c8e7c5cddafcffcb8997336d523a5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movements of the dow jones index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1781032202,
                "headline": "Tuesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 140584945,
                "url": "https://finnhub.io/api/news?id=1aeabbcc77f9185172435c30e42f2efc2af24fc7d584a2c01e8709664fa18b50",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson agreed to acquire Firefly Bio for $1 billion in a move to expand its oncology pipeline. The deal adds degrader-antibody conjugate technology focused on KRAS-driven cancers to Johnson & Johnson's research efforts. The acquisition is aimed at strengthening Johnson & Johnson's position in cancer therapeutics beyond its existing portfolio. For investors tracking NYSE:JNJ, this acquisition comes with the stock at a share price of $232.16 and multi-year returns that have been...",
                "category": "company",
                "datetime": 1781028615,
                "headline": "Johnson And Johnson Buys Firefly Bio To Deepen Oncology Growth Story"
              },
              {
                "id": 140584874,
                "url": "https://finnhub.io/api/news?id=1f4c087b2c44ca1cfdcf748e8790b150910bf2efa9437646ea0fda106e6ca111",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Nvidia, Visa and Microsoft lead the list of Wall Street's top Dow Jones stocks to buy now. Some other names might surprise you.",
                "category": "company",
                "datetime": 1781026172,
                "headline": "All 30 Dow Jones Stocks Ranked: Buy, Sell or Hold?"
              },
              {
                "id": 140582052,
                "url": "https://finnhub.io/api/news?id=a42f628a93dc75f3e17052b515f94d3c527d61005ac81f3a1d1e07a3e661dda4",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the top performers within the dow jones index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1781023202,
                "headline": "Stay informed with the top movers within the dow jones index on Tuesday."
              },
              {
                "id": 140585400,
                "url": "https://finnhub.io/api/news?id=bd3bcd959d21ed59acce7beee1a9305e211d320f613c8082f66b265a28538f8c",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 10:00 AM EDTCompany ParticipantsTom Cavanaugh - Company...",
                "category": "company",
                "datetime": 1781021532,
                "headline": "Johnson & Johnson (JNJ) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript"
              },
              {
                "id": 140581313,
                "url": "https://finnhub.io/api/news?id=f79ae9a858709f0f1c6a6b96aaea9a3fc1ce93aaa4a5d751b5c047522b07151d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A 65-year-old retiree with $1 million who follows the standard 4% rule withdraws $40,000 in the first year, then increases that amount over time to keep pace with inflation. A dividend-focused alternative starts slightly lower, at about $38,000 in annual income from a 3.8% blended yield, but does not require selling shares. Over 20 years, ... The Dividend Strategy That Beats the 4% Rule by $400,000 Over 20 Years on a $1 Million Portfolio",
                "category": "company",
                "datetime": 1781019961,
                "headline": "The Dividend Strategy That Beats the 4% Rule by $400,000 Over 20 Years on a $1 Million Portfolio"
              },
              {
                "id": 140583208,
                "url": "https://finnhub.io/api/news?id=70fbac04c5b4a0afa77a419b341f7ac7db2cfa9b9d1858138765bd9496cf4ac6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ is set to acquire Firefly Bio for $1 billion in cash, adding its Firelink DAC platform and advancing efforts in KRAS-driven cancer treatments.",
                "category": "company",
                "datetime": 1781018160,
                "headline": "J&J to Expand Cancer Pipeline With $1B Firefly Bio Acquisition"
              },
              {
                "id": 140583209,
                "url": "https://finnhub.io/api/news?id=48f4534c3de1f9cf7047a4f7b211a3e69858988754a760dcf50732e92055aeec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.",
                "category": "company",
                "datetime": 1781017440,
                "headline": "JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?"
              },
              {
                "id": 140581395,
                "url": "https://finnhub.io/api/news?id=f6dd0c579f370406123673781cc8eb32f47114a334d145dead978e82650d9d01",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Vascarta Inc. is proud to announce the addition of Richard Serbin to its leadership team to serve in the role of Chief Strategy Officer. Richard Serbin will work closely with Vascarta's leadership to identify and evaluate new strategic partnership or acquisition opportunities that leverages his extensive experience as Johnson & Johnson's former Executive Vice President of Corporate Development.",
                "category": "company",
                "datetime": 1781016600,
                "headline": "Vascarta Announces Addition of Richard Serbin to Leadership Team"
              },
              {
                "id": 140581396,
                "url": "https://finnhub.io/api/news?id=26cd38edd15ad124891c81ff7768f3f755caa29394d17773c4c3f8f6a75a10ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In recent weeks, Johnson & Johnson reported positive late‑stage data and regulatory milestones across multiple therapies, including TECVAYLI in relapsed/refractory multiple myeloma, amivantamab-based regimens in lung and head and neck cancers, and a TREMFYA label update in psoriatic arthritis. These advances, alongside progress for nipocalimab in systemic lupus erythematosus and Sjögren's disease and expanded frontline use of Darzalex in the UK, highlight how Johnson & Johnson is broadening...",
                "category": "company",
                "datetime": 1781014361,
                "headline": "The Bull Case For Johnson & Johnson (JNJ) Could Change Following Key Oncology And Immunology Pipeline Wins - Learn Why"
              },
              {
                "id": 140581397,
                "url": "https://finnhub.io/api/news?id=562b3b62ae3e13805553d9ea41df60e2a2bf29ac30e18f2584c70a8c7b660c86",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) has rallied 13.73% year to date and 55.27% over the past year, fueled by oncology blockbusters and a MedTech franchise hitting on every cylinder. CEO Joaquin Duato told investors that “Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth ... Will Johnson & Johnson Stock Hit $300 This Year?",
                "category": "company",
                "datetime": 1781014007,
                "headline": "Will Johnson & Johnson Stock Hit $300 This Year?"
              },
              {
                "id": 140581380,
                "url": "https://finnhub.io/api/news?id=b25f2ba1d76a0bb5ca3674fd706a5a772bf02928dcae6ee3275a03a209b2cabc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.",
                "category": "company",
                "datetime": 1781013540,
                "headline": "Middle East Erupts Again: Buy these Healthcare ETFs Before the Next Strike"
              },
              {
                "id": 140584947,
                "url": "https://finnhub.io/api/news?id=e75a5cc65645bbaa67a789e1ef5131cd5659ca759f28581ebedec432ed13c08c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Tango Therapeutics shares rallied on Monday after recording impressive results for its pancreatic cancer drug. Here’s how you should play TNGX stock at current levels.",
                "category": "company",
                "datetime": 1781011791,
                "headline": "Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results"
              },
              {
                "id": 140579466,
                "url": "https://finnhub.io/api/news?id=2f434515bf6af4f2a6f5797954f12d510483d1183df51277f639b68ad0256ef7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $1.2 million portfolio generating $7,200 per month produces $86,400 in annual income, equivalent to a blended yield of 7.2%. According to the Social Security Administration’s 2026 COLA fact sheet, the average aged couple receiving Social Security benefits collects about $3,208 per month, or $38,496 per year. That means a portfolio generating $7,200 per month ... A Portfolio That Doubles Your Social Security Check—and Your Spouse’s",
                "category": "company",
                "datetime": 1781004994,
                "headline": "A Portfolio That Doubles Your Social Security Check—and Your Spouse’s"
              },
              {
                "id": 140579467,
                "url": "https://finnhub.io/api/news?id=b076333ec9e4173d71a6e12cb4e214904cd594322304af3da7c4e80b232099a3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The transaction is expected to close later this year, subject to regulatory approvals and other customary closing conditions.",
                "category": "company",
                "datetime": 1781002790,
                "headline": "J&J to acquire Firefly Bio for $1bn to enhance oncology pipeline"
              },
              {
                "id": 140578878,
                "url": "https://finnhub.io/api/news?id=f6ca94774fa9815a6dadd77bdf0b54ad3aceb24ab70b0f3166e27860be7ea872",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NICE has preliminarily recommended D-VRd for NHS use as a first-line treatment for transplant-ineligible multiple myeloma.",
                "category": "company",
                "datetime": 1780998420,
                "headline": "J&J secures extended NICE approval for Darzalex following earlier refusal"
              },
              {
                "id": 140578879,
                "url": "https://finnhub.io/api/news?id=a9126afff04d45c525f359c7c2bfe23ec205911256d2bb472a6bb7e2d01382b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Five thousand dollars a month in spendable dividend income works out to $60,000 per year after federal tax, roughly equivalent to the salary of a typical police officer in Indiana. The headline yield shown on a brokerage statement does not tell the full story. Taxes, the type of distributions received, and future dividend growth all ... Get Paid Like an Indiana Police Officer With $5,000 a Month in Dividend Income After Taxes",
                "category": "company",
                "datetime": 1780996080,
                "headline": "Get Paid Like an Indiana Police Officer With $5,000 a Month in Dividend Income After Taxes"
              },
              {
                "id": 140580818,
                "url": "https://finnhub.io/api/news?id=2666975a9da11891ff12de319e74f9cdd02aea5e9637329ab359639c4b988841",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.gov.uk/government/news/nipocalimab-imaavy-authorised-to-treat-adults-and-adolescents-with-generalised-myasthenia-gravis",
                "category": "company",
                "datetime": 1780994352,
                "headline": "Johnson & Johnson's Nipocalimab Gets U.K.'s Medicines And Healthcare Products Regulatory Agency Authorization To Treat Adults And Adolescents With Generalised Myasthenia Gravis"
              },
              {
                "id": 140579747,
                "url": "https://finnhub.io/api/news?id=312e05ce278692d553c1de96c1ca517b8d91342c0c5b9b4e71fc7ef4c36d3323",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458573871/image_458573871.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Kenvue Inc. outlook: near-term headwinds, but a 5% yield and undervalued forward P/E under 15x ahead of the KMB merger. Click for this KVUE stock update.",
                "category": "company",
                "datetime": 1780993800,
                "headline": "Kenvue: After A Disappointing 3 Years, Kimberly-Clark's Gamble Could Revive Growth"
              },
              {
                "id": 140574215,
                "url": "https://finnhub.io/api/news?id=11d768d0d79ebdbab100836ba74f65008d6b572472c947aec26c21479b8302ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Firelink platform delivers protein-degrading drugs directly into KRAS-driven tumor cells",
                "category": "company",
                "datetime": 1780949432,
                "headline": "J&J Pays $1 Billion to Crack an Undruggable Cancer Target"
              },
              {
                "id": 140574200,
                "url": "https://finnhub.io/api/news?id=c231254cf9bb4eb792a519edc2d69c2c6e85818ad128330e28bca83dff16073d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "More than a simple climb, the drugmaker's stock re-rated on a growth story that somehow keeps getting bigger.",
                "category": "company",
                "datetime": 1780948199,
                "headline": "Why Is Lilly Stock Growing Like A Silicon Valley Tech Darling?"
              },
              {
                "id": 140570797,
                "url": "https://finnhub.io/api/news?id=4a922969e3a72653625804e5bd4ff12b016e0c6bdd67823934efa0a4f14ca25e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A retiree’s $40,000 dividend income stream sounds modest next to a neighbor’s $90,000. But the growth rate often matters more than the starting number. A portfolio generating $40,000 today that grows its income by 8% annually produces roughly $86,000 in ten years and more than $186,000 in twenty. That is the power of compounding. The ... The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000",
                "category": "company",
                "datetime": 1780940085,
                "headline": "The Dividend Growth Portfolio That Starts at $40,000 a Year and Ends at $150,000"
              },
              {
                "id": 140570780,
                "url": "https://finnhub.io/api/news?id=643a97a7bf197deee54560e65f79d3b49c5f2f572954f8993c245a6e30e07a4f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV climbs 12% a month as investors weigh the raised 2026 guidance, Skyrizi and Rinvoq growth, and multiple pipeline updates.",
                "category": "company",
                "datetime": 1780935480,
                "headline": "Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month?"
              },
              {
                "id": 140568956,
                "url": "https://finnhub.io/api/news?id=8e5d7f68a88feed38e1bd2d74c7ee25803e44a8c28f211247a4560ccca79bc10",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generating $7,500 per month in dividend income requires producing $90,000 annually from an investment portfolio. That income level is roughly equivalent to the salary of a registered nurse, based on recent U.S. Bureau of Labor Statistics wage data. As a result, it serves as a useful benchmark for households pursuing financial independence or planning for ... How to Replace a Registered Nurse’s Salary with $7,500 a Month in Dividend Income",
                "category": "company",
                "datetime": 1780931582,
                "headline": "How to Replace a Registered Nurse’s Salary with $7,500 a Month in Dividend Income"
              },
              {
                "id": 140568957,
                "url": "https://finnhub.io/api/news?id=8b1c2215f0c76256dec1968bc44fd676ebd7876166aef2a9c143a553184c4c78",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) said Monday that it has agreed to acquire cancer drug developer Firefly Bio",
                "category": "company",
                "datetime": 1780930237,
                "headline": "Johnson & Johnson to Acquire Firefly Bio in $1 Billion Deal"
              },
              {
                "id": 140567758,
                "url": "https://finnhub.io/api/news?id=5b0da577418547ee25b6b3a54048613ac3004df2a8f3191156cca38bb4f12d8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The deal targets KRAS-driven tumors, which J&J says have limited treatment options and survival measured in months",
                "category": "company",
                "datetime": 1780925594,
                "headline": "Johnson & Johnson acquires Firefly Bio for $1 billion"
              },
              {
                "id": 140567759,
                "url": "https://finnhub.io/api/news?id=20d807a5d537447ac939b5e56888e9cd3631d45980fc7e809a38a7ea86e2ca58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The biotech giant is bucking the market trend, but its real value for investors lies in a story that unfolds over years, not days.",
                "category": "company",
                "datetime": 1780924024,
                "headline": "Can MariTide Save Amgen Stock From Its Fading Blockbusters?"
              },
              {
                "id": 140567750,
                "url": "https://finnhub.io/api/news?id=cf6678ed653f7e19ba5fc0ee0edc7e523529d976f3c600f1c93027559e5232d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The drugmaker's recent outperformance is a sideshow to its more valuable, long-term trait for investors.",
                "category": "company",
                "datetime": 1780923345,
                "headline": "Is AbbVie Stock The Right Defensive Pick In This Volatile Market?"
              },
              {
                "id": 140567761,
                "url": "https://finnhub.io/api/news?id=4163dff5d57c895056e1ba445cf0de37058b3f50a20793206ed4f6e82a6cc67a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is one of the cheap robotics stocks to buy right now. On May 12, Johnson & Johnson (NYSE:JNJ) confirmed the global launch of the Shockwave C2 Aero Coronary IVL Catheter for the treatment of calcified coronary artery disease, as it seeks to redefine the standards of coronary IVL with efficient, predictable […]",
                "category": "company",
                "datetime": 1780920089,
                "headline": "Johnson & Johnson (JNJ): A Cheap Robotics Stock Redefining Coronary Artery Disease Treatment"
              },
              {
                "id": 140567762,
                "url": "https://finnhub.io/api/news?id=1befbb3b377d791faf4e2351f6f4e4d181237d25e624e744462cc2fbf9227716",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., June 08, 2026--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform for KRAS-driven tumors bolsters Johnson & Johnson’s oncology pipeline and ambition to develop targeted medicines for the most prevalent and hard-to-treat solid tumors with high unmet need1.",
                "category": "company",
                "datetime": 1780920000,
                "headline": "Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform"
              },
              {
                "id": 140568958,
                "url": "https://finnhub.io/api/news?id=36c367ac51a35915b1336df5fb818b3e2106e800735e651598a5f4183d1548dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.",
                "category": "company",
                "datetime": 1780917960,
                "headline": "J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B"
              },
              {
                "id": 140566919,
                "url": "https://finnhub.io/api/news?id=45602532c10e0efdd7fc3efa928965f21497408ad05a51d708bd1715decc1e81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "BOSTON, June 08, 2026--Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress",
                "category": "company",
                "datetime": 1780916700,
                "headline": "Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress"
              },
              {
                "id": 140570217,
                "url": "https://finnhub.io/api/news?id=cd2b59e7bfc5042499f05592bff048bb843534e3715a937097778ea105f0aabd",
                "image": "https://image.cnbcfm.com/api/v1/image/108318126-17809265551780926553-46420418821-1080pnbcnews.jpg?v=1780926554&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Watch the opening bell for the New York Stock Exchange, the Nasdaq and Cboe from June 8, 2026.",
                "category": "company",
                "datetime": 1780912268,
                "headline": "Opening Bell: June 8, 2026"
              },
              {
                "id": 140549738,
                "url": "https://finnhub.io/api/news?id=3ded0cb9e65b0ba7b66b00e6eff473507a47f8fc4743bc595f9d86c00b0b02b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson takes a licking, and the dividend keeps on ticking higher.",
                "category": "company",
                "datetime": 1780756500,
                "headline": "Why Johnson & Johnson May Be the Closest Thing Investors Can Find to a Bulletproof Dividend Stock"
              },
              {
                "id": 140549000,
                "url": "https://finnhub.io/api/news?id=8f9ffccee92cc3b5be8c5f367c25d0d4778484276d52da920d0b7223dcd69021",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Investing for Beginners Podcast recently revisited one of the most influential ideas in modern finance. That was Benjamin Graham’s concept of buying with a margin of safety. In fact, according to host Andrew Sather, Graham’s Columbia students went on to compound capital at extraordinary rates using the same principles applied to wildly different portfolios. ... These Investors Earned 20% to 33% Returns Using The Same Philosophy on Completely Different Stocks",
                "category": "company",
                "datetime": 1780753335,
                "headline": "These Investors Earned 20% to 33% Returns Using The Same Philosophy on Completely Different Stocks"
              },
              {
                "id": 140547811,
                "url": "https://finnhub.io/api/news?id=e67f06f1c7d59c328c63ab674d337b6ac5600d075da589ba1eb982cde2ccf48d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Wondering whether Kenvue at around US$17.71 offers good value or just looks cheap on the surface? This article breaks down what that price really implies for you as a shareholder. The stock has inched up 2.5% over the last week and 0.2% over the last month, yet is still down 14.7% over the past year and up 2.3% year to date. This naturally raises questions about risk, sentiment, and entry points. Recent coverage has focused on Kenvue as a stand alone consumer health company following its...",
                "category": "company",
                "datetime": 1780733245,
                "headline": "Does Kenvue (KVUE) Offer Value After Share Price Decline And DCF Upside Projection"
              },
              {
                "id": 140544122,
                "url": "https://finnhub.io/api/news?id=7f12a13c39ecbcdd30f2566a129f3d2950f4311ff3d4e8263ced98ff27fa2e27",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market capital structure, and is relatively cheaply valued. But is that enough.",
                "category": "company",
                "datetime": 1780700116,
                "headline": "Is Amgen An Undervalued Stock Or Value Trap?"
              },
              {
                "id": 140542504,
                "url": "https://finnhub.io/api/news?id=311d853d6980ee1bd26e8b783321881b41d9d7da380ff0fa6a71ebd1f693fdd4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "US stocks (^DJI, ^IXIC, ^GSPC) sink in Friday trading, the Nasdaq Composite leading losses and closing over 1,100 points lower (4.18%). The market is reacting to May's overwhelmingly positive labor data — 172,000 jobs added the US economy vs. estimates of 88,000 — raising investor concerns that the Federal Reserve may be inclined to hike interest rates. Yahoo Finance Markets and Data Editor Jared Blikre breaks down the day's biggest market moves.",
                "category": "company",
                "datetime": 1780690297,
                "headline": "Nasdaq plunges 1,100 points over renewed rate hike concerns"
              },
              {
                "id": 140542569,
                "url": "https://finnhub.io/api/news?id=0eaeedae1c58038f9fb6157bedc28ca118778cebbb78eaa3e1f516d6c67f19f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In May 2026, Laser Photonics Corporation disclosed that Nasdaq had notified the company it was out of compliance due to a delayed Form 10-Q filing for the quarter ended March 31, 2026, starting a process that could eventually lead to delisting if the issue is not resolved within Nasdaq’s prescribed timelines. This filing setback comes as Laser Photonics is gaining higher visibility from U.S. defense evaluations of its Laser Shield Anti-Drone system, a major Navy follow-on contract for laser...",
                "category": "company",
                "datetime": 1780689919,
                "headline": "Why Laser Photonics (LASE) Is Up 288.5% After Nasdaq Noncompliance Notice Amid Defense Contract Momentum"
              },
              {
                "id": 140539925,
                "url": "https://finnhub.io/api/news?id=67d833f5b24fce6dbe3ff721315ea785526bbc8589ca0f73f184e32061192f42",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Curious about the top performers within the dow jones index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1780686602,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 140543177,
                "url": "https://finnhub.io/api/news?id=dac56ba14da07903909a43ce802535e2e0859607b50ad353cf39d06d13b45db3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Get this week’s dividend updates for Champions, Contenders & Challengers—see hikes/cuts, upcoming ex-dividend dates and pay dates.",
                "category": "company",
                "datetime": 1780683596,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of June 7"
              },
              {
                "id": 140542570,
                "url": "https://finnhub.io/api/news?id=7c66a3f9a02ec571d7a6ed66179db18393dce2153880bc95b515f116c9a33a3d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "CereVasc is developing a minimally invasive treatment for the buildup of fluid in the brain.",
                "category": "company",
                "datetime": 1780678080,
                "headline": "J&J, Medtronic back CereVasc’s $85M funding round"
              },
              {
                "id": 140537117,
                "url": "https://finnhub.io/api/news?id=809cc7899f17b93e7809acf4549bbe5e66e1d40842132eb8d1159a155801f8d7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Friday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1780677602,
                "headline": "Friday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 140540032,
                "url": "https://finnhub.io/api/news?id=a6a8089ecc2310efd81d33b3134038a90860c25c50958e1fd3973b10b9ea6a35",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/",
                "category": "company",
                "datetime": 1780669486,
                "headline": "U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts"
              },
              {
                "id": 140536594,
                "url": "https://finnhub.io/api/news?id=3dea2a4bbd11f3c523898526b76f3fb2ab4770f0d842dc69d8f22455427ae37a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Kimberly-Clark Corporation (NASDAQ:KMB) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer called it an “odd one,” as he commented: We need some staples. I’ve got an odd one. How about a stock I haven’t talked about at all? How about Kimberly-Clark? Here’s a premier Kleenex […]",
                "category": "company",
                "datetime": 1780668864,
                "headline": "Jim Cramer Says He Likes “Kimberly-Clark Because It’s Merging With Kenvue”"
              },
              {
                "id": 140536584,
                "url": "https://finnhub.io/api/news?id=cab200024248cc2867f74d268b0881df09bc2efeaa9f25315e0b3bf1771bddf4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in out-of-favor sectors. Cramer highlighted the company’s billion-dollar drugs and growing businesses, as he stated: So I’m going to do something completely out of favor and recommend one that we’re buying for the Charitable Trust gingerly, as […]",
                "category": "company",
                "datetime": 1780668863,
                "headline": "Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations"
              },
              {
                "id": 140535446,
                "url": "https://finnhub.io/api/news?id=42a245846b652f5869ce75da390d4ba6e40337e45dbb5083bbe0e9182a01f554",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Replacing $36,000 a year in income is roughly equivalent to generating the cash flow from a maximum Social Security benefit for a single retiree, or about $3,000 a month before taxes. A 66-year-old with $850,000 in a taxable brokerage account can build that income stream using five Dividend Aristocrats, relying on companies with decades-long records ... Five Boring Dividend Aristocrats That Quietly Pay $36,000 a Year on $850,000 Without a Single Yield Trap",
                "category": "company",
                "datetime": 1780665483,
                "headline": "Five Boring Dividend Aristocrats That Quietly Pay $36,000 a Year on $850,000 Without a Single Yield Trap"
              },
              {
                "id": 140536596,
                "url": "https://finnhub.io/api/news?id=042a576ceafaf07fdfa9f23ab797e1bf9b283028a0e1e726567ffeee37c9d881",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J faces Stelara erosion, China MedTech pressure and talc litigation, but targets $100B revenues and faster growth in 2026.",
                "category": "company",
                "datetime": 1780664820,
                "headline": "Can JNJ Sustain Growth Amid Patent, Legal and China Risks?"
              },
              {
                "id": 140535447,
                "url": "https://finnhub.io/api/news?id=ab11a4c42b172e8381fed6f731b5972c904cb9a6d64326d270f74d5e214e67b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Five Dividend Aristocrats with streaks ranging from 54 to 70 consecutive years of payout hikes are currently trading below Wall Street’s consensus price targets, and four of the five just beat their most recent EPS estimates. When a 64-year dividend raiser like Johnson & Johnson is raising 2026 EPS guidance to $11.45-$11.65 while still trading ... Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target",
                "category": "company",
                "datetime": 1780661947,
                "headline": "Dividend Aristocrats on Sale: 5 Decades-Long Raisers Trading Below Target"
              },
              {
                "id": 140531824,
                "url": "https://finnhub.io/api/news?id=67f5632202d3c0aff271a8a9ca45f8300c16159e6faf317ce66c29adae816b72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Here are three top-rated consumer dividend stocks that have yields above 3% and have made their way onto the coveted Zacks Rank #1 (Strong Buy) list.",
                "category": "company",
                "datetime": 1780615380,
                "headline": "Best Consumer Dividend Stocks to Buy Now: HAS, KVUE, MOV"
              },
              {
                "id": 140530722,
                "url": "https://finnhub.io/api/news?id=721e60f6ba42fa26392de53ed181c71b097a62a452911e94f84dac5cdaf99b5e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $228.17, marking a +2.21% move from the previous day.",
                "category": "company",
                "datetime": 1780609503,
                "headline": "Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider"
              },
              {
                "id": 140529196,
                "url": "https://finnhub.io/api/news?id=98563e070f218beb08d1937b82b1b05e59101258b21fdfeca3825868ec2cfcf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) reported multiple milestone clinical results at ASCO 2026 in autoimmunity, oncology, and myeloma. New data included the first FcRn-blocker efficacy signals in systemic lupus erythematosus and promising results in Sjögren's disease. Phase 3 PROTEUS data for apalutamide plus hormone therapy around surgery in high-risk localized prostate cancer were described as practice changing. TECVAYLI showed statistically significant survival benefits in relapsed or refractory...",
                "category": "company",
                "datetime": 1780608006,
                "headline": "ASCO 2026 Data Underscore Johnson & Johnson’s Expanding Specialty Drug Story"
              },
              {
                "id": 140529191,
                "url": "https://finnhub.io/api/news?id=cef88c4e5f0946619db8eea5444bae921c67c68ab802d27a88bbc6ca7403336b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Even without its metabolic business, management argues Eli Lilly (LLY) would be one of the fastest-growing pharmaceutical companies in the industry. This is not a single-product story. The company's immunology, oncology, and neuroscience medicines collectively grew by 160%, showing the depth of its R&D engine.",
                "category": "company",
                "datetime": 1780604608,
                "headline": "75% Upside For LLY Stock?"
              },
              {
                "id": 140526815,
                "url": "https://finnhub.io/api/news?id=28b511993e7df406f34ed7accd0f25f68249254bdcff3a5b88df4f960ddffc46",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1780600202,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 140537538,
                "url": "https://finnhub.io/api/news?id=0737524fd08ef630fc6c9d16e12f06c6760f2b08c1f59c16d69ecc682a891b4d",
                "image": "https://image.cnbcfm.com/api/v1/image/108316785-1780584404017-gettyimages-2279812222-mms18765_bxyw1a1n.jpeg?v=1780584477&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "The S&P 500 is on track to finish the week slightly higher, which would mark its 10th straight week of gains and its longest win streak since 1985.",
                "category": "company",
                "datetime": 1780596158,
                "headline": "Nasdaq falls the most in nearly 8 months as chips tumble; S&P 500's 9-week winning streak set to end: Live updates"
              },
              {
                "id": 140524206,
                "url": "https://finnhub.io/api/news?id=5e178280abf5bb889c7bc6709bca47d65f3a252b18edc158043e32d0bcf521af",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1780591202,
                "headline": "Top dow jones movers in Thursday's session"
              },
              {
                "id": 140525325,
                "url": "https://finnhub.io/api/news?id=b513f115c4d70b580db954c2fd0ea3004e58bc3904c423d34a2cf9afc1241ace",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Newsweek, in partnership with Plant-A Insights Group, today announced the World’s Greenest Companies 2026, recognizing the top 850 companies across 28 countries for their performance in environmental sustainability. Rising emissions, deforestation, and record-setting temperatures continue to shape a more unpredictable climate, with extreme weather becoming more common worldwide. Recognizing these challenges, many companies are taking meaningful steps t",
                "category": "company",
                "datetime": 1780588800,
                "headline": "Goldman Sachs, Johnson & Johnson, MetLife Named Among Newsweek’s World’s Greenest Companies 2026"
              },
              {
                "id": 140523549,
                "url": "https://finnhub.io/api/news?id=d01cdc61fff46a6c8875d0dac499684e05633668e48ab452e5bccba19983991c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "CereVasc’s eShunt is an implantable system designed to treat normal pressure hydrocephalus by draining excess cerebrospinal fluid.",
                "category": "company",
                "datetime": 1780584553,
                "headline": "CereVasc raises $85m to advance hydrocephalus treatment"
              },
              {
                "id": 140542571,
                "url": "https://finnhub.io/api/news?id=f5b7e6e4cba1a4c8e54e683f1c990e491f8e1bbff66444b0e48c8013d1087eef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) stands out as a candidate for multi-decade portfolios because it pairs a AAA credit rating with 64 consecutive years of dividend increases, a combination almost no other public company in the world can match. For a retirement-focused investor who is tired of watching a portfolio bounce on every headline, this is ... This Dividend King Is the Safest Dow Stock to Buy and Hold for 20 Years",
                "category": "company",
                "datetime": 1780582331,
                "headline": "This Dividend King Is the Safest Dow Stock to Buy and Hold for 20 Years"
              },
              {
                "id": 140523550,
                "url": "https://finnhub.io/api/news?id=eb9f24991dd3aee917388f98c0a3f2f3bb825449517b11615ff5edeac55ea041",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "At the 24% federal bracket, a portfolio throwing off $40,000 in high-yield dividend income hands roughly $9,600 to the IRS every year when those shares sit in a taxable account treated as ordinary income. For investors in the gap years between retirement and RMD age 73, that drag compounds quietly until required minimum distributions force ... How to Maximize Dividend Income in Retirement Before RMDs Change the Math",
                "category": "company",
                "datetime": 1780581619,
                "headline": "How to Maximize Dividend Income in Retirement Before RMDs Change the Math"
              },
              {
                "id": 140522290,
                "url": "https://finnhub.io/api/news?id=b289290a5863bee8852f58f10b93ae1dc7569d8855dca9be5643c648820004f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "At the 37% top federal bracket, a portfolio throwing off $60,000 in non-qualified dividend income hands the IRS $22,200 every April, before state taxes and before the 3.8% net investment income tax (NIIT) surtax that also applies at this income level. That is the cost of holding REITs, BDCs and other ordinary-income dividend payers in ... Without a Roth, $60,000 in Dividend Income From These 5 Stocks Means You Owe the IRS $22,200",
                "category": "company",
                "datetime": 1780578914,
                "headline": "Without a Roth, $60,000 in Dividend Income From These 5 Stocks Means You Owe the IRS $22,200"
              },
              {
                "id": 140521459,
                "url": "https://finnhub.io/api/news?id=57928755a0feb285dec308b2357bf92b245b85ed8a030e596d1eddd7add0016c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Social Security Administration (SSA) set the 2026 cost-of-living adjustment (COLA) at 2.8%, lifting the average retired worker’s benefit from $2,015 to $2,071 per month. That extra $56 sounds fine on paper. Then the Medicare Part B premium notice arrives, the Medigap renewal letter shows up, and the math gets tighter than expected. One retiree ... Why Social Security’s 2.8% COLA Isn’t Keeping Up With What Retirees Actually Spend on Healthcare",
                "category": "company",
                "datetime": 1780573541,
                "headline": "Why Social Security’s 2.8% COLA Isn’t Keeping Up With What Retirees Actually Spend on Healthcare"
              },
              {
                "id": 140521458,
                "url": "https://finnhub.io/api/news?id=2888b189b23adc488f5b9b6c28e5762dd25693195d83cb704ad045e6aea4b76c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A combined household income of $110,000 is close to the national norm for a two-earner household. For a 56-year-old couple hoping to retire at age 60 and fund their lifestyle entirely through dividend income, that annual amount becomes the income target their portfolio must replace. The basic calculation is straightforward: divide the desired income by ... Can Pure Dividend Stocks Replace a $110,000 Dual-Income Household Income? Here’s What It Would Take",
                "category": "company",
                "datetime": 1780570316,
                "headline": "Can Pure Dividend Stocks Replace a $110,000 Dual-Income Household Income? Here’s What It Would Take"
              },
              {
                "id": 140521461,
                "url": "https://finnhub.io/api/news?id=cf45748026e310e0ae1e1b01287a064fee0306ac86572196d3d106a894d66a81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "CereVasc, Inc., a clinical-stage medical device company developing novel, minimally invasive treatments for neurological diseases, today announced it has successfully completed the initial closing of an $85 million Series C financing. Piper Sandler Merchant Banking led the financing with participation from Johnson & Johnson Innovation – JJDC, Inc., Johnson & Johnson's corporate venture capital arm, and Medtronic, along with existing investors Bain Capital Life Sciences and Perceptive Xontogeny V",
                "category": "company",
                "datetime": 1780567200,
                "headline": "CereVasc, Inc. Announces Over-Subscribed $85 Million Series C Financing to Advance its Novel eShunt® System for the Treatment of Normal Pressure Hydrocephalus"
              },
              {
                "id": 140530125,
                "url": "https://finnhub.io/api/news?id=f0a1287ca16889c8b8ab686ad6136c74aee9887b571c477d5aa21f312da2ab91",
                "image": "https://cdn.benzinga.com/files/images/story/2026/06/04/Investor-Planning-And-Strategy--Stock-Ma_1.jpeg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Laser Photonics Corp (NASDAQ:LASE) stock dips on Thursday. Read why traders are taking profits ahead of Q1 earnings despite major Department of War and Johnson & Johnson deals.",
                "category": "company",
                "datetime": 1780563820,
                "headline": "Why Is Laser Photonics Stock Falling On Thursday?"
              },
              {
                "id": 140520404,
                "url": "https://finnhub.io/api/news?id=f24b4c12383d1e4b4500fae5faab4231a2f725dc44170160823bd936ab4a720a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Marc Verbruggen Managing Director, Purna Pharmaceuticals Puurs, Belgium, June 04, 2026 (GLOBE NEWSWIRE) -- Purna Pharmaceuticals (“Purna”), a specialty contract development and manufacturing organization and portfolio company of Ampersand Capital Partners (“Ampersand”), today announced the appointment of Marc Verbruggen as Managing Director, effective June 1, 2026. Purna specializes in the development, manufacture and supply of liquid and semi-solid pharmaceutical products. Dr. Stefan Beyer, who",
                "category": "company",
                "datetime": 1780556520,
                "headline": "Purna Pharmaceuticals Names Marc Verbruggen as Managing Director"
              },
              {
                "id": 140513311,
                "url": "https://finnhub.io/api/news?id=ebd861180fcb78573359ce78f6c72956695c7f3e8dc937b0b4a2fb609e530255",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.",
                "category": "company",
                "datetime": 1780519500,
                "headline": "Medtronic Stock Is Defying a Market Selloff After Earnings. Here’s Why."
              },
              {
                "id": 140515847,
                "url": "https://finnhub.io/api/news?id=f12eae3674694cf425f50d042292f0735b68447f2c30d7b4dfe9d35bd11e5ca5",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1780513802,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 140513835,
                "url": "https://finnhub.io/api/news?id=7e1cb0184f6aeb9ddbe16925bff29adde63c5afab579bff30d0eeaf1f3ab0d26",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Wednesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1780504802,
                "headline": "Top dow jones movers in Wednesday's session"
              },
              {
                "id": 140514977,
                "url": "https://finnhub.io/api/news?id=4c0db5e5e8accd03c4bfec2651e0045d689645f8081bfd98490de9abf2bfafab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
                "category": "company",
                "datetime": 1780501503,
                "headline": "Are You Looking for a High-Growth Dividend Stock?"
              },
              {
                "id": 140513201,
                "url": "https://finnhub.io/api/news?id=737a68264409df4db25759ab229cb32d5249b25c0559bceedf6be1d9b00303b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.",
                "category": "company",
                "datetime": 1780495740,
                "headline": "Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?"
              },
              {
                "id": 140514848,
                "url": "https://finnhub.io/api/news?id=4ae6d440810993e5624e2ff3059aaee8f18c3b41ed347cde7d32c88775c4506a",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": " ",
                "category": "company",
                "datetime": 1780493726,
                "headline": "10 Health Care Stocks Whale Activity In Today's Session"
              },
              {
                "id": 140513202,
                "url": "https://finnhub.io/api/news?id=ac668076cf4b3ac6e32a36d15cf2f487d5ec24f965761eab26049b22ed4b005a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1780491606,
                "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 140512143,
                "url": "https://finnhub.io/api/news?id=a7f079bc610ee531f003b66062f1b920160daa013cf16dc3d2bb2c163dcb057e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ChemE Show 2026 Powered by ACHEMA opens June 9-10 at the George R. Brown Convention Center in Houston, Texas. Produced by Gulf Energy Information, publisher of Hydrocarbon Processing, and powered by ACHEMA, the inaugural event brings together engineers, plant managers, R&D teams, and technical decision-makers from across the chemicals, pharmaceutical and biopharma, hydrogen, and broader process industries for two days of technology discovery, expert programming, and industry connection.",
                "category": "company",
                "datetime": 1780490820,
                "headline": "The Expanding Frontier of Chemical Engineering: ChemE Show 2026 Opens June 9-10 in Houston"
              },
              {
                "id": 140511337,
                "url": "https://finnhub.io/api/news?id=be30192078f0aa04a8b685615067bcc21154ec18ba030c906c00e5919c86731a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched. This article walks through exactly what ... This Is What a $1 Million Dividend Portfolio Pays After Taxes",
                "category": "company",
                "datetime": 1780487127,
                "headline": "This Is What a $1 Million Dividend Portfolio Pays After Taxes"
              },
              {
                "id": 140515511,
                "url": "https://finnhub.io/api/news?id=92441dd0906fe01ebc99777f7bdcb1152339919ae26b5016f43f0d3196d43918",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b and continued to demonstrate sustained",
                "category": "company",
                "datetime": 1780459990,
                "headline": "Johnson & Johnson Reports Lupus Study Results for Nipocalimab"
              },
              {
                "id": 140515512,
                "url": "https://finnhub.io/api/news?id=584533c547b4fdbd2779079024e6707db23fdc38c3f6c281ec2d416cc4f867f9",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) today announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sjögren's disease",
                "category": "company",
                "datetime": 1780459931,
                "headline": "Johnson & Johnson Reports New Sjögren's Disease Data for Nipocalimab"
              },
              {
                "id": 140509915,
                "url": "https://finnhub.io/api/news?id=d5273ffdd09684ee0d307e4c80b4ff6227f260f6e5e47031681678d44a822935",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SLE Responder Index 4 (SRI-4)b and continued to demonstrate sustained reduction in disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE)a through 52 weeks in the Phase 2 JASMINE study as measured by both SRI-4b and Lupus Low Disease Activity State (LLDAS).c In addition, the study results showed greater response versus placebo",
                "category": "company",
                "datetime": 1780459440,
                "headline": "Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study"
              },
              {
                "id": 140509916,
                "url": "https://finnhub.io/api/news?id=76d47f448cb7c4c743388408224acfabacb4648f66a3745d8824abe06493714d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today announced new biomarker exploratory analyses from the Phase 2 DAHLIAS study evaluating nipocalimab in adults with moderate-to-severe Sjögren's disease (SjD)a showing that participants with elevated autoantibody and immunoglobulin G (IgG) levelsb, who are often those who experience more substantial disease burden, showed greater clinical response rates.1 These data will be presented in an oral session at the 2026 European Alliance of Associations for Rheumatolo",
                "category": "company",
                "datetime": 1780459380,
                "headline": "Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease"
              },
              {
                "id": 140508339,
                "url": "https://finnhub.io/api/news?id=6348ce27d58f95fda929e273b69a03104e78a5d032b601f3f1146cce1660706e",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "GMO’s $39B 13F shows shifts into quality large-cap tech & healthcare—adding Microsoft, Broadcom, Salesforce while trimming Lam, Wells Fargo. See more.",
                "category": "company",
                "datetime": 1780434018,
                "headline": "Tracking Jeremy Grantham's GMO Capital Portfolio - Q1 2026 Update"
              },
              {
                "id": 140506241,
                "url": "https://finnhub.io/api/news?id=04a5558237754b0ab446d5952473e1d534a2063f64406ba1399a9433a8f79420",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million, including issuance of pre-funded warrants to accelerate the development of Company’s other platformsNew data from Part 1 of the J&J sponsored Phase 2 CONVERGE study, evaluating JNJ-1900 (NBTXR3) for patients with Stage 3 inoperable non-small cell lung cancer (NSCLC), presented at the 2026 annual European Society for Radiotherapy and Oncology (ESTRO)Announced FDA acceptance of a protocol amendm",
                "category": "company",
                "datetime": 1780432200,
                "headline": "Nanobiotix Provides First Quarter 2026 Operational and Financial Update"
              },
              {
                "id": 140514218,
                "url": "https://finnhub.io/api/news?id=1f28d7f137230234b0ecd887a19db893111bd33c7f848a427463525765e30d27",
                "image": "https://image.cnbcfm.com/api/v1/image/3ED3-MM-A-BLOCK-060226.jpg?v=1780488277&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "'Mad Money' host Jim Cramer looks at buying opportunities outside of tech in the current market.",
                "category": "company",
                "datetime": 1780428551,
                "headline": "Jim Cramer looks at stocks that will go higher if tech retreats"
              },
              {
                "id": 140508729,
                "url": "https://finnhub.io/api/news?id=627a37027a5fd136ae6b4143addbf27a24562f75b28af2cf46b5030fb13b33f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.",
                "category": "company",
                "datetime": 1780426970,
                "headline": "Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF"
              },
              {
                "id": 140504249,
                "url": "https://finnhub.io/api/news?id=ce9728b1882a7e04cbd8d8b20d28d4adf0ebb30bc6412c5b7a5b91050055a7e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie's shareholders can sleep easy.",
                "category": "company",
                "datetime": 1780426200,
                "headline": "Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic"
              },
              {
                "id": 140499226,
                "url": "https://finnhub.io/api/news?id=7a707e85ba947c5234fcf8120abe52c951245ba710035192670cb2659f7d4d99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes, today announced the appointment of Steve Glover to its B",
                "category": "company",
                "datetime": 1780405200,
                "headline": "Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer"
              },
              {
                "id": 140486619,
                "url": "https://finnhub.io/api/news?id=87508c1c70b79cd60cc2b27d704002b52305ed1c3459e505fdcf738b36a8a911",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Persistent inflation is likely to keep the Federal Reserve from cutting rates until well into 2027. Rising costs in services, housing, energy, and tariffs continue to keep inflation above the Fed’s 2% target, while the labor market remains strong enough to support wage pressures. Because of this, the Fed is expected to keep rates higher ... No Rate Cuts Until 2027? Grab These High-Yielding Safe Dividend Kings Now",
                "category": "company",
                "datetime": 1780316404,
                "headline": "No Rate Cuts Until 2027? Grab These High-Yielding Safe Dividend Kings Now"
              },
              {
                "id": 140489025,
                "url": "https://finnhub.io/api/news?id=f35c3449d702a2b4b68ce3c374909e9f3a4eff061f87752aaef3a97f78616b8a",
                "image": "https://image.cnbcfm.com/api/v1/image/108314497-17803178951780317887-46286941861-1080pnbcnews.jpg?v=1780317894&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "Jason Gerberry, BofA Securities senior large-cap pharma analyst, joins 'Squawk Box' to discuss the 2026 ASCO Annual Meeting, what to expect from the conference, latest cancer treatment announcements, and more.",
                "category": "company",
                "datetime": 1780304341,
                "headline": "2026 ASCO Annual Meeting: BofA's Jason Gerberry on what to expect"
              },
              {
                "id": 140484732,
                "url": "https://finnhub.io/api/news?id=46f859c1131095d8ed297157b20ddd9da2b6ab5764b1c81a946a9da8fb105b25",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Some investors may be wondering whether Johnson & Johnson at around US$225 per share still offers value, or if most of the opportunity is already reflected in the price. The stock is up 48.6% over the past year and 8.7% year to date, even though it has slipped 3.8% in the last week and 0.8% over the past month. This mixed performance may have some investors reassessing the balance between potential upside and risk. Recent news coverage has focused on Johnson & Johnson's position as a large,...",
                "category": "company",
                "datetime": 1780297890,
                "headline": "Is It Too Late To Consider Johnson & Johnson (JNJ) After Its 48% One-Year Surge?"
              },
              {
                "id": 140488848,
                "url": "https://finnhub.io/api/news?id=8af69a1d5bf417245bed4bb2aab558d30da03e9faf6715a1caa763ea11b684ad",
                "image": "https://image.cnbcfm.com/api/v1/image/107300086-1694616035094-gettyimages-1662734382-AFP_33V44H7.jpeg?v=1771381842&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "The AI-Driven Enterprise Institute released new research that breaks down the degree to which S&P 500 companies are adopting AI compared with their peers.",
                "category": "company",
                "datetime": 1780296909,
                "headline": "Nvidia, Meta and Schlumberger rank among top companies in adopting AI, new study says"
              },
              {
                "id": 140483747,
                "url": "https://finnhub.io/api/news?id=11596b8cda6538b72eb6fd6e13a74b63894ae8ffcc57fa3aac3baff13b703787",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Dividend Paying Stocks to Buy Right Now. Johnson & Johnson (NYSE:JNJ) and its subsidiaries develop, manufacture, and sell a broad range of healthcare products, giving the company a presence across multiple areas of the healthcare industry. The company’s dividend remains one of its biggest attractions […]",
                "category": "company",
                "datetime": 1780283986,
                "headline": "Is Johnson & Johnson (JNJ) One of the Best Dividend Paying Stocks to Buy Right Now?"
              },
              {
                "id": 140478297,
                "url": "https://finnhub.io/api/news?id=a67e8b937a365322f92d24697355cd594adb76776d57af85ca7ef4d4dc9315bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The income target is straightforward: $12,500 a month equals $150,000 a year, and the portfolio doing the work is $2.8 million. Dividing the income by the capital gives the math the whole article has to solve: a blended yield of roughly 5.4%. That number falls in the middle of the income-investing spectrum, which is why ... How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier",
                "category": "company",
                "datetime": 1780249289,
                "headline": "How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier"
              },
              {
                "id": 140486620,
                "url": "https://finnhub.io/api/news?id=727db422995fbae32e6b287b7441cd7da06861b32c1c6dadea9225678a63416f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential",
                "category": "company",
                "datetime": 1780233900,
                "headline": "3 Dividend Kings That Earn Their Crown Every Quarter"
              },
              {
                "id": 140476882,
                "url": "https://finnhub.io/api/news?id=6a9c186f707ec917059aad1c308e0ad2c16c189b51a96850eda13bc4c82d987f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Compared with patients receiving hormone therapy alone, patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20 percent reduction in the risk of developing metastasis or death1 Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journal of Medicine1,2 BEERSE, BELGIUM, May 31, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the final analysis of the Phase 3 PROTEUS study sh",
                "category": "company",
                "datetime": 1780231140,
                "headline": "Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, versus hormone therapy alone, potentially shifting a decades-long treatment paradigm"
              },
              {
                "id": 140476883,
                "url": "https://finnhub.io/api/news?id=e0cb7a3503017be33fb922c6ebb903e22f36f8dd749a653e0884bbcbab5e8eba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) today announced pivotal results from the Phase 1b/2 OrigAMI-4 study showing that subcutaneous amivantamab and hyaluronidase-lpuj delivered durable responses in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. Confirmed overall response rate was 42 percent, with more than one-third of responders achieving complete responses. Median duration of response was not yet reached, with a median follow up of",
                "category": "company",
                "datetime": 1780230540,
                "headline": "RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited"
              },
              {
                "id": 140476884,
                "url": "https://finnhub.io/api/news?id=d2b1673c7629ce9c49c1baddabcda45dfadfaee09aba0916e72ff47080459659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation therapy, ADT), given for six months before and after prostate cancer surgery, significantly improved key short- and long-term clinical outcomes for patients with high-risk localized or locally advanced disease. The trial met both primary endpoints. Patients treated with apalutamide plus hormone therapy",
                "category": "company",
                "datetime": 1780229700,
                "headline": "Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm"
              },
              {
                "id": 140473514,
                "url": "https://finnhub.io/api/news?id=15327c54938e1365384fd686748644fb2d84284fbf3231d7116b0bdb914ae49d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Nanobiotix (ENXTPA:NANO) has closed a global equity offering to fund continued development of its lead product candidate JNJ-1900 (NBTXR3). The raise followed promising early results from a Johnson & Johnson sponsored Phase 2 trial in stage 3 inoperable non small cell lung cancer, presented at ESTRO 2026. The company plans to use the new capital to progress its oncology pipeline, with a focus on JNJ-1900 (NBTXR3). For investors tracking ENXTPA:NANO, the combination of fresh equity funding...",
                "category": "company",
                "datetime": 1780178646,
                "headline": "Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally"
              },
              {
                "id": 140469513,
                "url": "https://finnhub.io/api/news?id=eb8d5f0693d4bc6786d700b26093c1dffbdc5bec3b9b03ae09ed378915afad8d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "High energy prices have investors worried about a recession; these businesses should survive the hit just fine.",
                "category": "company",
                "datetime": 1780148100,
                "headline": "How to Recession-Proof Your Retirement Income Before Summer 2026"
              },
              {
                "id": 140469558,
                "url": "https://finnhub.io/api/news?id=58b934356ebcec801dced209246009967e533247e189d888b56eb718696ec403",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generating $5,000 per month in passive income works out to $60,000 annually, a level many retirees target to cover core expenses without relying heavily on Social Security or selling assets during market downturns. At a 6% portfolio yield, reaching that income level requires roughly $1 million invested. The harder question is not simply reaching the yield ... The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns",
                "category": "company",
                "datetime": 1780147105,
                "headline": "The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns"
              },
              {
                "id": 140468519,
                "url": "https://finnhub.io/api/news?id=f51efb9482bf37335ee4f5cbec37d0bf7129a30e99f7cc1f457e2f419ed59fa2",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Johnson & Johnson offers a reliable 2.31% dividend yield with consistent growth, backed by strong profitability and solid solvency, making it a top pick for passive income investors.",
                "category": "company",
                "datetime": 1780134627,
                "headline": "Johnson & Johnson (NYSE:JNJ): A Classic Dividend Stock for Sustainable Passive Income"
              },
              {
                "id": 140468521,
                "url": "https://finnhub.io/api/news?id=1b942a955da0048d4e7de7a9aacf5010c3c0a29ee6f1be8767cc1eaac6cc9b2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Walmart is facing short-term pressures that are leading investors to miss the long-term opportunity.",
                "category": "company",
                "datetime": 1780134300,
                "headline": "This Dividend King Stock Just Offered a Superb Buy-the-Dip Opportunity"
              },
              {
                "id": 140461542,
                "url": "https://finnhub.io/api/news?id=307ca33b28586ceb0be655c992ec7e9352d21a9719102052a442a9830ce0b7d8",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Friday.",
                "category": "company",
                "datetime": 1780081802,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 140471017,
                "url": "https://finnhub.io/api/news?id=f5cc2b3f0a8cb4bdb93cf4b78f324745d23a7060590144fb3019acfce2f2d843",
                "image": "https://image.cnbcfm.com/api/v1/image/108314164-6ED1-REQ-052926-MMABLOCK.jpg?v=1780094615&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "'Mad Money' host Jim Cramer looks at Dell's massive upswing.",
                "category": "company",
                "datetime": 1780081254,
                "headline": "Jim Cramer looks ahead to next week's market game plan"
              },
              {
                "id": 140462163,
                "url": "https://finnhub.io/api/news?id=72fdb67fb101f14c0336a15d8dc3a73120335eea27401ca4adfe4313f17e34b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) today announced updated results from the Phase 1/1b CHRYSALIS-2 study evaluating intravenous RYBREVANT® (amivantamab-vmjw) in combination with LAZCLUZE® (lazertinib) in patients with advanced non-small cell lung cancer (NSCLC) with atypical epidermal growth factor receptor (EGFR) mutations. The analysis showed encouraging long-term outcomes with RYBREVANT® plus LAZCLUZE® in this difficult-to-treat population. Median overall survival, a secondary endpoint, was nearly",
                "category": "company",
                "datetime": 1780077600,
                "headline": "RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer"
              },
              {
                "id": 140465738,
                "url": "https://finnhub.io/api/news?id=7253124319748ca880773b613c4f726a83adff87853cf6e406bb67d8b28ac36d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options activity suggests the medical devices giant could be a potential acquisition target. Here's a closer look at why.",
                "category": "company",
                "datetime": 1780075802,
                "headline": "Unusual Options Activity Points to Boston Scientific Stock as a Hot M&A Target"
              },
              {
                "id": 140470463,
                "url": "https://finnhub.io/api/news?id=10a41df76022d6ee1f52be70adb93814c69eea3cc51d40ad869dd07d48a11934",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated diseaseConsistent responses observed across atypical EGFR",
                "category": "company",
                "datetime": 1780063439,
                "headline": "Johnson & Johnson Announces Updated Results From Phase 1/1b CHRYSALIS-2 Study Evaluating Intravenous RYBREVANT In Combination With LAZCLUZE In Patients With Advanced NSCLC With Atypical EGFR Mutations"
              },
              {
                "id": 140458223,
                "url": "https://finnhub.io/api/news?id=b31a879e347c2aac414fb18eb63f5895f0d5725b4abebace00f63eb0621b6ba2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Vanguard High Dividend Yield Index Fund ETF Shares (NYSEARCA:VYM) is one of the simplest income vehicles in the market: it owns roughly 500 U.S. stocks that pay above-average dividends, weights them by market cap, and passes the cash through to shareholders. VYM tracks the FTSE High Dividend Yield Index, which excludes REITs and screens ... VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks",
                "category": "company",
                "datetime": 1780063298,
                "headline": "VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks"
              },
              {
                "id": 140462164,
                "url": "https://finnhub.io/api/news?id=29f8abfb719884f5f98dd950ff84f8323e6f52aae8f93bf4731f608b7703bb2c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.",
                "category": "company",
                "datetime": 1780061598,
                "headline": "AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?"
              },
              {
                "id": 140457110,
                "url": "https://finnhub.io/api/news?id=ace2a5c2124877d78025c435183a931c6ec84aafc1b036002c737555e30aed44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Passive income arrives on its own schedule, no effort required. Dividends keep landing in the brokerage account on a predictable schedule, regardless of headlines or market moves. High-yield, blue-chip dividend stocks offer something real estate and most alternative income vehicles cannot: liquidity and flexibility. You can buy and sell on a Tuesday morning, reinvest distributions ... Want $1,400 in Passive Income? Invest $10,000 Into These 4 Dividend Stocks",
                "category": "company",
                "datetime": 1780057801,
                "headline": "Want $1,400 in Passive Income? Invest $10,000 Into These 4 Dividend Stocks"
              },
              {
                "id": 140457111,
                "url": "https://finnhub.io/api/news?id=bcd87e73ccb96ebe29e4d606be57a6a75733267bccb0025e1f66c524ca8ed8ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of Johnson & Johnson’s TECVAYLI® as early as second line1TECVAYLI® delivered deep and durable responses, with nearly two-thirds of patients achieving a complete response or better2 Beerse, Belgium, May 29, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival (PFS) and",
                "category": "company",
                "datetime": 1780057440,
                "headline": "New TECVAYLI®▼ (teclistamab) data demonstrate superior progression-free and overall survival versus standard of care as early as first relapse in multiple myeloma"
              },
              {
                "id": 140457112,
                "url": "https://finnhub.io/api/news?id=7979f796d8926955860882c00fc59ab9562107daf4fad799429c1157198374d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with TECVAYLI® (teclistamab-cqyv) versus standard of care regimens in patients with relapsed or refractory multiple myeloma treated as early as second line. In a patient population whose myeloma was predominantly refract",
                "category": "company",
                "datetime": 1780057020,
                "headline": "New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma"
              },
              {
                "id": 140458691,
                "url": "https://finnhub.io/api/news?id=4515a7aaeac48843f6bd636ba178c4d533c9dd49909da06cec14c62291dd3cb2",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced new data from the Phase 3 MajesTEC-9 study demonstrating clinically meaningful and statistically significant",
                "category": "company",
                "datetime": 1780042919,
                "headline": "Johnson & Johnson Announces New Data From Its Phase 3 MajesTEC-9 Study That Show Clinically Meaningful And Statistically Significant Survival Improvements With TECVAYLI In Patients With Relapsed Or Refractory Multiple Myeloma"
              },
              {
                "id": 140459445,
                "url": "https://finnhub.io/api/news?id=669ace83a9d3dd4f57dcbc8bafbaa07adc96b6cb5e9dcc05ece5e67459c31e99",
                "image": "https://image.cnbcfm.com/api/v1/image/108313737-17800555791780055575-46230772510-1080pnbcnews.jpg?v=1780055578&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "CNBC’s Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's cancer drug pipeline, impact of GLP-1 drugs on cancer growth, FDA leadership overhaul, global drug pricing, and more.",
                "category": "company",
                "datetime": 1780042255,
                "headline": "J&J CEO Joaquin Duato: It's our mission to become the number 1 company in oncology by 2030"
              },
              {
                "id": 140455995,
                "url": "https://finnhub.io/api/news?id=a0f4562a6d7535f330b5d492b483505347da9231e41df8a3a8b6d04ac0def385",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154591716/image_2154591716.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Compass Pathways advances COMP360 psilocybin for TRD, with Phase 3 success and a rolling NDA by 4Q26. Learn more about CMPS stock here.",
                "category": "company",
                "datetime": 1780036836,
                "headline": "Compass Pathways: A Psychedelics Story"
              },
              {
                "id": 140458692,
                "url": "https://finnhub.io/api/news?id=6cff8bb78bc45c29fa4f4d4564d20072cacfecdedeb32cb190193ad009dc9438",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence in the TREMFYA® (guselkumab)",
                "category": "company",
                "datetime": 1780028385,
                "headline": "Johnson & Johnson Wins FDA Nod for New TREMFYA Benefit in Psoriatic Arthritis Treatment"
              },
              {
                "id": 140452297,
                "url": "https://finnhub.io/api/news?id=8673d896f93d32e412e904fb83e5cc453d85d414c26bfd597e2c832705cba04d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). The inclusion of this key outcome reflects that TREMFYA is the only IL-23 inhibitor proven to help stop further structural damage, offering patients with active PsA a first-li",
                "category": "company",
                "datetime": 1780009800,
                "headline": "FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage"
              },
              {
                "id": 140459247,
                "url": "https://finnhub.io/api/news?id=a93c86cfe165eced422ef03a916c22cfd96e6905386199fc87ae8cf2cb9ed8a3",
                "image": "https://image.cnbcfm.com/api/v1/image/108273478-1772635556929-gettyimages-2264175653-APPLE_LAUNCH.jpeg?v=1772635586&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "The S&P 500 and the Nasdaq Composite closed at new records on Thursday as the tech sector jumped. Both indexes are on pace for healthy May gains.",
                "category": "company",
                "datetime": 1779997791,
                "headline": "Friday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 140452298,
                "url": "https://finnhub.io/api/news?id=b4c3919d6abad740a4387f5c8716fea2c32c6efa0fb93c25cc424c7c64aad3d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Congressional Budget Office (CBO) released a report this year containing one number that should change how every American near retirement thinks about income. Here's 3 dividend stocks to replace that lost income.",
                "category": "company",
                "datetime": 1779987138,
                "headline": "3 Dividend Kings to Buy Now to Replace the Social Security Income You're About to Lose"
              },
              {
                "id": 140444611,
                "url": "https://finnhub.io/api/news?id=0f50004312d571e1057d95736aea778aa03168c24e78ca006c3e727dd7087200",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) owns only companies with at least 10 consecutive years of dividend growth, screens out the highest yielders, and lets compounding work. VIG has returned 22% over the past year and 244% over the past decade, a track record that owes as much to its tech-heavy roster as to traditional ... Microsoft’s AI Spending Won’t Derail Dividend Safety Inside Vanguard’s VIG",
                "category": "company",
                "datetime": 1779977392,
                "headline": "Microsoft’s AI Spending Won’t Derail Dividend Safety Inside Vanguard’s VIG"
              },
              {
                "id": 140443440,
                "url": "https://finnhub.io/api/news?id=bb517c26cfea39b887a47c9444e6688dcc2a372846ac0e7ed87500c390f960de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "John Slump, co-founder and former president and CEO of Atraverse Medical, announced the launch of Metis MedTech, an investment and strategic advisory platform for medical device founders. The launch follows the close of Johnson & Johnson's acquisition of Atraverse Medical on May 15, 2026, which strengthens its J&J MedTech cardiac electrophysiology portfolio.",
                "category": "company",
                "datetime": 1779975480,
                "headline": "John Slump Launches Metis MedTech Following Atraverse Medical Acquisition by Johnson & Johnson"
              },
              {
                "id": 140444706,
                "url": "https://finnhub.io/api/news?id=97a2aa0ad0a407849e3c60191180f95fa4eda3cc428ae46e7bdd4ce5ce7b34f5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "category": "company",
                "datetime": 1779975004,
                "headline": "Is Johnson & Johnson (JNJ) a Buy as Wall Street Analysts Look Optimistic?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 1,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.3,
            "source_article_count": 245,
            "discarded_article_count": 216
          },
          "sentimentPoints": 3
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.3,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 1.4,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1.4,
            "vcp_reason": "站上MA50；升放量(近10日2日)；收盤突破20日高位；Ready=N；Confirm=Y",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 8668513.333333334,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 10569340,
              "avg_vol_20": 8701310,
              "avg_vol_30": 8668513.333333334,
              "range_pct_10": 0.07307219392236074,
              "range_pct_20": 0.10798348849464257,
              "range_pct_30": 0.10798348849464257,
              "up_expand_ok": true,
              "lookback_used": 79,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": true,
              "vol_ratio_10_30": 1.2192794304598173,
              "dist_to_20d_high": -0.009844789356984475,
              "down_shrink_days": 0,
              "breakout_level_20d": 225.5,
              "vcp_breakout_confirm": true,
              "contraction_ratio_10_30": 0.676697844652297
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 1.6,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 2,
            "details": {
              "atrPct": 1.8882838573686982,
              "turnoverUsdM": 2055.51458,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.JNJ",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 219.12,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2.5,
              "rsi_score": 0.5,
              "macd_score": 3,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 3.8,
            "take_profit_price": 239.106,
            "target_multiplier": 1.9,
            "technical_strength": 1.92,
            "take_profit_percent": 5
          },
          "positionPoints": 2,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.3239534883720931,
          "stopLossPercent": 3.7765677147373964,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 4.3,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.89
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 143.5
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "強累積",
      "score": 10,
      "value": 0.3251
    },
    "kdj": {
      "d": 89.5,
      "j": 97.48,
      "k": 92.16,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "強資金流入",
      "score": 10,
      "value": 70.64
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 282712700,
      "recentSlope": 1379850,
      "previousSlope": 3890670
    },
    "rsi": 84.23,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 214.5561,
      "position": "SAR喺價下",
      "distancePct": 5.78,
      "previousTrend": "上升"
    },
    "ma50": 208.8708,
    "macd": {
      "macd": 4.901804357954546,
      "trend": "強烈看漲",
      "signal": 3.7717092397528953,
      "histogram": 1.130095118201651
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 214.1818,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 12
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.01,
      "score": 6,
      "avgVolume": 8935190,
      "currentVolume": 9026500
    },
    "derived": {
      "ma20": 213.8295,
      "ma50": 208.8708,
      "prevClose": 224.44,
      "avgVolume10": 10334030,
      "avgVolume20": 8935190,
      "changePercent": 1.46,
      "avgVolumeForScore": 8935190
    },
    "ma_cross": {
      "ma20": 213.8295,
      "ma50": 208.8708,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 212.8215,
      "prevMa50": 208.2214,
      "spreadPct": 2.37,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 199.2555,
      "upper": 228.4035,
      "position": "上半部"
    },
    "rsi_short": 97.98,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.01
    }
  }
}

{
  "close": 227.72,
  "volume": 9026500,
  "changePercent": 1.46
}